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Purpose of the review: Pancreatic cancer is extremely aggressive, forming highly
chemo-resistant tumors, and has one of the worst prognoses. The evolution of this
cancer is multi-factorial. Repeated acute pancreatic injury and inflammation are important
contributing factors in the development of pancreatic cancer. This article attempts to
understand the common pathways linking pancreatitis to pancreatic cancer.
Recent findings: Intracellular activation of both pancreatic enzymes and the transcription
factor NF-κB are important mechanisms that induce acute pancreatitis (AP). Recurrent
pancreatic injury due to genetic susceptibility, environmental factors such as smoking,
alcohol intake, and conditions such as obesity lead to increases in oxidative stress,
impaired autophagy and constitutive activation of inflammatory pathways. These
processes can stimulate pancreatic stellate cells, thereby increasing fibrosis and
encouraging chronic disease development. Activation of oncogenic Kras mutations
through inflammation, coupled with altered levels of tumor suppressor proteins (p53 and
p16) can ultimately lead to development of pancreatic cancer.
Summary: Although our understanding of pancreatitis and pancreatic cancer has
tremendously increased over many years, much remains to be elucidated in terms of
common pathways linking these conditions.
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INTRODUCTION: PANCREATIC ANATOMY, PHYSIOLOGY,
AND PATHOLOGY
The pancreas is a glandular organ of the digestive system con-
sisting of (a) an endocrine component which secretes insulin,
glucagon, and stomatostatins, and (b) an exocrine component
that produces numerous digestive enzymes and 1500–2000ml of
iso-osmotic alkaline fluid which is released into the small intes-
tine every day. The exocrine pancreas is composed of both acinar
and ductal cells; acinar cells (or acini) are responsible for syn-
thesis, storage and secretion of both active (amylase, lipase) and
inactive enzymes (zymogens; trypsinogen) (Ogami and Otsuki,
1998). Over 100 years ago it was first documented that the hor-
mone secretin could stimulate pancreatic secretion. Since then
it has become clear that pancreatic secretion is maintained and
modulated by a complex interaction between neural, hormonal
and mucosal factors (Bayliss and Starling, 1902). Gastric acid
influx into the small intestine initiates the release of secretin from
duodenal S-cells which then stimulates the release of bicarbon-
ate from pancreatic ductal cells to buffer this increase in intestinal
acid. Cholecystokinin (CCK) is released from duodenal endocrine
I-cells in response to proteins and fats in the small intestine. CCK
stimulates acinar cells both directly (Murphy et al., 2008) and
indirectly via stimulation of vagal nerve responses which acti-
vate muscarinic acetylcholine receptors on the acinar cell. This
results in release of pancreatic enzymes into the small intestine.
These normal physiological responses can be altered by many
factors that can ultimately lead to pathological responses and
development of pancreatitis and pancreatic cancer (Bayliss and
Starling, 1902; Ogami and Otsuki, 1998; Weiss et al., 2008). This
review will focus on common pathways that link the progression
from acute to chronic pancreatitis (CP) and finally pancreatic
cancer.
EPIDEMIOLOGY
Acute pancreatitis (AP) is a clinical syndrome which begins with
acute injury to the pancreas. It is one of the most frequent causes
of hospitalization, amounting to nearly 275,000 hospital admis-
sions every year in the United States at a cost of $2.6 billion
(Spanier et al., 2008). The most common causes of pancreatitis
include alcohol, gallstones, toxins, hyperlipidemia, and trauma,
with a small number of cases remaining idiopathic. These fac-
tors initiate distinct changes in pancreatic physiology causing
pathological activation of digestive enzymes within acinar cells,
decreased pancreatic enzyme secretion, increased inflammatory
responses and ultimately cell death (Spanier et al., 2008; Peery
et al., 2012). Traditionally AP is self-limited with complete resolu-
tion of function after the acute event. In some cases there may be
tissue scarring and stricture formation leading to pancreatic flow
obstruction and recurrent AP. The link between recurrent acute
and CP is unclear. Studies have shown that recurrent episodes of
pancreatitis set into motion various inflammatory pathways that
can lead to immunological and inflammatory responses. This in
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turn leads to increased fibrotic tissue formation and stellate cell
activation, well known hallmarks of CP.
CP is a fibro-inflammatory disease involving the pancreatic
parenchyma which is progressively destroyed and replaced by
fibrotic tissues. Histologically, acinar cell damage, mononuclear
cell infiltration, and fibrosis are observed (Shrikhande et al.,
2003). Traditionally, CP was thought of as a separate disease but
years of research have concluded that AP, recurrent AP andCP can
be part of the same disease continuum. There are various causes
thatmay lead to CP, but the exact pathophysiology of the disease is
still unclear. Three stages of CP development have been described
starting with stage one, the pre-pancreatitis phase, which is asso-
ciated with risk factors for CP such as alcohol, smoking and
genetic mutations. This is followed by stage two in the form of
AP, with release of inflammatory cytokines. If the attack is severe
enough it could activate macrophage dependent stellate cells
which ultimately lead to fibrosis, particularly if there is a contin-
uous stimulus causing interplay between pro-inflammatory and
anti-inflammatory pathways. Finally there is stage three which
is a progression to CP driven by factors that modulate immune
responses (Whitcomb, 2011, 2012). Thus CP develops due to
complex interactions between an impaired immune response to
low grade inflammation and environmental factors that decrease
the threshold for recurrent AP like alcohol intake and smoking.
CP has long been thought of as a strong risk factor for pancre-
atic cancer. Among patients with CP, a meta-analysis has shown a
relative risk of 13.3 for developing pancreatic cancer (Raimondi
et al., 2010). Chronic inflammation associated with CP facili-
tates this progression to cancer resulting in the occurrence of
three types of precancerous lesions: pancreatic intraepithelial
neoplasia (PanINs), intraductal papillary mucinous neoplasms
(IPMN), and mucinous cystic neoplasms (MCN). Subsequent
evolution of these precursor lesions into pancreatic ductal ade-
nocarcinoma (PDAC) ultimately involves a number of diverse
molecular changes (Yonezawa et al., 2008). Despite the strong link
between CP and pancreatic cancer, less than 5% of patients with
CP actually go on to develop the disease (Raimondi et al., 2010).
Pancreatic cancer is an extremely aggressive, invariably deadly
disease without any improvements in patient outcome over the
last 2 decades. With over 45,220 new cases of pancreatic can-
cer diagnosed every year in the USA the estimated number of
deaths in 2013 is projected to be around 39,000 making pan-
creatic cancer the fourth leading cause of cancer deaths in the
USA (Yadav and Lowenfels, 2013). The most effective treatment
is early resection of the cancer but this is not always possi-
ble because of late presentations and aggressive metastasis with
chemo-resistance. So only 20% of cases are eligible for surgery
and without surgery the median survival is only 6 months with a
5 year survival of 3–5% (Vincent et al., 2011; Siegel et al., 2012;
Yadav and Lowenfels, 2013). Pancreatic cancer is not prevalent in
patients under 20 years of age; the median age at onset is 71 years
(Yadav and Lowenfels, 2013). Hereditary pancreatitis is a severe
risk factor for pancreatic cancer with a lifetime risk of develop-
ing pancreatic cancer of 40–55% (Yadav and Lowenfels, 2013).
Smoking increases the risk of cancer in these patients and low-
ers the median age of diagnosis from 71 in non-smokers to 56 in
smokers (Howes et al., 2004).
Although epidemiology of the disease is well known, the
underlying cellular mechanisms of disease initiation and progres-
sion are less clear. Chemotherapeutic agents like gemcitabine have
been approved for pancreatic cancer not amenable to surgery, but
have not shown clear therapeutic effects (Lohr and Jesenofsky,
2009). In order to understand the complexities of molecular
mechanisms and drug interactions various mouse models have
been developed (Lee et al., 1995; Colby et al., 2008; Jung et al.,
2011). In the following sections, common cellular pathways in
pancreatitis and pancreatic cancer will be considered, and their
role in the transformation of acute to chronic disease, and ulti-
mately cancer, will be discussed.
COMMON CELLULAR PATHWAYS IN TRANSFORMATION OF
PANCREATITIS TO PANCREATIC CANCER
Premature activation of digestive zymogens and generation of
inflammatory mediators are key initiating events in pancreatitis.
Furthermore, these incidents can form the basis for progres-
sion from acute to CP and even pancreatic cancer (Figure 1). A
FIGURE 1 | Common pathways associated with disease progression
from acute to chronic pancreatitis and pancreatic cancer. Pancreatitis
starts with an initiating insult followed by changes in the cellular
environment and premature digestive enzyme activation. Mutations of
genes associated with trypsinogen activation/inactivation predispose the
pancreas to development of disease. As disease progresses defective
autophagy, increased inflammation, pancreatic stellate cell activation, and
fibrosis occur. Advancement toward pancreatic cancer and metastasis is
also associated with defective autophagy, as well as extracellular matrix
degradation, cell proliferation, expression of oncogenic Kras and loss of
tumor suppressors (e.g., P16 and P53). Autophagy and inflammation are
discussed further in Figures 2, 3.
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detailed review of these molecular events and their relevance in
disease advancement follows.
ROLE OF PREMATURE TRYPSINOGEN ACTIVATION
During pancreatitis lysosomal enzymes are mistargeted to
zymogen-containing organelles within the acinar cell. The lyso-
somal hydrolase cathepsin-B prematurely converts the digestive
zymogen, trypsinogen, to its active form, trypsin (Figarella et al.,
1988; Gorelick and Matovcik, 1995; Lerch et al., 1995; Wartmann
et al., 2010). This conversion requires an acidic pH and cathepsin-
B activates trypsinogen in a pH dependent manner (Kukor et al.,
2002). In addition, cleavage of trypsinogen to active trypsin
requires the folding of its N-terminal upon itself to form a globu-
lar molecule, a process which is also pH dependent (Nemoda and
Sahin-Toth, 2005). It has been shown that a low pH environment
sensitizes acinar cells to secretagogue induced zymogen activation
and cell injury. This process is mediated by a vacuolar ATPase
(vATPase) and the effects of low pH on zymogen activation can be
blocked by the vATPase inhibitor concanamycin (Bhoomagoud
et al., 2009). Once trypsinogen has been activated, trypsin can
activate more trypsinogen (autoactivation), and additional zymo-
gens, resulting in autodigestion of the pancreas. Inhibition (Van
Acker et al., 2002) or genetic deletion (Halangk et al., 2000)
of cathepsin B has been shown to attenuate trypsinogen activa-
tion and pancreatic inflammation. There are various protective
mechanisms to counter trypsinogen activation, mainly through
inhibition or degradation of activated trypsin. These mechanisms
include inhibition by Serine protease inhibitor, Kazal type 1 also
known as pancreatic secretory trypsin inhibitor (SPINK1/PSTI)
and degradation by chymotrypsin-C (CTRC). In addition, the
lysosomal hydrolase cathepsin-L degrades trypsinogen to an
inactive form of trypsin thus providing protection against pre-
mature zymogen activation. Paradoxically, when cathepsin-L is
genetically deleted there is also a switch from acinar cell necro-
sis to apoptosis with reduced severity of disease (Wartmann
et al., 2010). This indicates that cathepsin L may be involved
in additional pathways which contribute to pancreatitis. For
the most part though, when these protective mechanisms are
overwhelmed there is an increased predisposition to develop
pancreatitis.
Activation of trypsinogen is thought to be the initiating
event in the cascade of zymogen activation associated with
pancreatitis. This is supported by work done in mice lacking
trypsinogen-7 (T−/−), an ortholog of human cationic trypsino-
gen (PRSS1). Hyperstimulation with the CCK ortholog cerulein
induced zymogen activation and pancreatitis in wild type mice,
whereas necrosis and cell death was significantly reduced in T−/−
mice (Dawra et al., 2011). However, no effect on inflammation
and NFκB activation was observed in T−/− mice (Dawra et al.,
2011) suggesting that other mechanisms are also involved in the
pathogenesis of AP. Another study found, using a cell free sys-
tem where acinar cell components can be reconstituted, that
activation of other zymogens, such as chymotrypsinogen and
procarboxypeptidase, can occur independently of trypsinogen
activation (Thrower et al., 2006). Thus development of pancre-
atitis appears to include both trypsin dependent and independent
events.
CP is associated with several genetic mutations related
to trypsin activation and inactivation. Cationic trypsinogen
(PRSS1) has several mutations which lead to chronic hereditary
pancreatitis (Whitcomb et al., 1996). The two most common
are replacement of the arginine at position 122 with histidine
(R122H) and replacement of the asparagine at position 29 with
isoleucine (N29I). These substitutions lead to increased autoacti-
vation of trypsinogen and elevated levels of active trypsin (Chen
and Ferec, 2009, 2012). Mutation of SPINK1 which encodes
an endogenous trypsin inhibitor has been described as disease-
predisposing rather than a disease causing factor (Witt et al.,
2000; Chen and Ferec, 2012). Moreover meta-analysis studies
conducted in Europe and America has shown idiopathic CP to
be strongly associated with SPINK1 mutations (Pfutzer et al.,
2000; Threadgold et al., 2002). Chymotrypsin-C (CTRC) pro-
tects against intra-cellular trypsin activity by degrading both
trypsinogen and trypsin. Mutations in PRSS1 render it resis-
tant to CTRC-dependent degradation (Szabo and Sahin-Toth,
2012) while mutation of CTRC results in an inability to inacti-
vate trypsinogen and trypsin resulting in increased levels of active
trypsin (Beer et al., 2013). Cystic fibrosis transmembrane conduc-
tance regulator (CFTR), an anion channel, allows the movement
of chloride and bicarbonate from ductal cells to the ductal lumen.
In mutations of CFTR that lead to decreased bicarbonate con-
ductance, but not chloride, there is a higher risk of idiopathic CP
especially when paired with mutation of SPINK1 (Mounzer and
Whitcomb, 2013). Ethanol has been shown to reduce CFTR func-
tion via depletion of ATP (Judak et al., 2013). Thus, inhibition of
CFTR activity whether by genetic mutation or ethanol exposure
can lead to both AP and CP (Choudari et al., 1999; Pezzilli et al.,
2003).
Pancreatic cancer can also be modulated by pathways associ-
ated with trypsinogen activation and inactivation. SPINK1 has
been shown to cause cell proliferation in pancreatic cell lines
by binding to the epidermal growth factor receptor (EGFR)
and stimulating the mitogen-activated protein kinase pathway
(MAPK). Both SPINK1 and EGFR were found in PDAC as well as
PanINs including early stage PanIN-1A but not in adjacent nor-
mal duct cells (Ozaki et al., 2009). A Japanese study of PDAC
for 23 patients (20 invasive and 3 non-invasive) found pan-
creatic trypsinogen in 70% of tumors, but not in any of the
non-invasive tumors. The trypsinogen activator, cathepsin-B, was
also found in 70% of invasive tumors but not in non-invasive
tumors. Metastatic peripancreatic neural plexuses and lymph
nodes also stained intensely positive for trypsinogen. In addition,
they stained positive for cathepsin B, but only weak to moderate
(Ohta et al., 1994). In a more recent paper it has been shown that
knockout of cathepsin B is associated with slowed PDAC progres-
sion, extended survival and decreased liver metastasis in a mouse
model (Gopinathan et al., 2012). This data suggests that pancre-
atic trypsinogen (expressed in PDAC) and cathepsin-B play a role
in PDAC progression and metastasis. Cathepsin-L which can pro-
tect against pancreatitis by degrading trypsinogen and trypsin
has a very different effect in cancer. In one study, cathepsin-L
expression levels in PDAC epithelium was associated with median
survival time. The median survival time for tumors expressing
high levels of cathepsin-L was 6 months while those expressing
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low levels was 22 months (Singh et al., 2013). This difference
may be due to the ability of cathepsin-L to degrade extracellular
matrix allowing for more tumor growth in those tumors express-
ing high levels of cathepsin-L.Mesotrypsinogen (PRSS3) has been
found to be overexpressed in pancreatic cancer cell lines and pro-
motes cell proliferation and invasion in cell culture, while in vivo
it causes both tumor growth and metastasis. This data suggests
that modulation of the PRSS3 signaling pathway may be a viable
approach for treating pancreatic cancer (Jiang et al., 2010).
CALCIUM SIGNALING
Aberrant increases in intracellular calcium levels are critical in
acinar cell injury. Localized transient calcium spikes constitute
a normal physiologic response whereas a sustained global rise
in calcium is a pathological response causing pancreatic injury
(Cancela et al., 2002; Petersen et al., 2011). Endoplasmic retic-
ulum ryanodine receptors (RyR) and plasma membrane store
operated calcium channels (SOC) are an important means of
elevating calcium in pancreatic acinar cells (Glitsch et al., 2002;
Parekh, 2003; Husain et al., 2005). For example, mice deficient
in the transient receptor potential cation channel, subfamily C,
member 3, (TRPC3), a SOC, have reduced calcium elevations in
secretagogue, bile acid, and alcohol metabolite-mediated mod-
els of pancreatitis (Kim et al., 2009, 2011). Furthermore, ethanol
abuse has been shown to impact calcium signaling. Ethanol in
the pancreas is converted via non-oxidative pathways into fatty
acid ethyl esters (FAEEs) which can cause release of calcium
from intracellular stores and premature trypsinogen activation
(Wilson et al., 1992; Wilson and Apte, 2003). Ethanol itself
does not cause pancreatitis in rats, but it has been reported to
worsen cerulein stimulated pancreatitis, suggesting synergistic
association. Ethanol causes a dose dependent sensitization of the
pancreas to CCK or cerulein mediated pancreatitis. Furthermore,
free radicals generated through ethanol metabolism and FAEEs
have been shown to damage mitochondrial membranes causing
ATP depletion (Wilson and Apte, 2003). This alters the bioen-
ergetics of acinar cells and favors necrosis over apoptosis. ATP
is also needed for calcium homeostasis and decreased ATP lev-
els cause further increases in pathological calcium levels in the
cytosol (Criddle et al., 2006).
Downstream targets of calcium include Protein-Kinase
C (PKC) and the calcium-sensitive phosphatase calcineurin
(Gukovskaya et al., 2004; Satoh et al., 2004; Cosen-Binker et al.,
2007; Thrower et al., 2008, 2009; Muili et al., 2012). FK506
(Tacrolimus), a macrolide immunosuppressant that inhibits cal-
cineurin has been shown to markedly reduce intra-pancreatic
protease activation and pancreatitis severity in cerulein models
of pancreatitis (Kim et al., 2011; Muili et al., 2012). Furthermore,
pharmacological or genetic blocking of calcineurin also reduces
acinar cell injury in a bile-acid induced model of pancreatitis
(Muili et al., 2012). Interestingly, recent studies have shown that
NFATc1, a calcineurin responsive transcription factor, is asso-
ciated with aggressive pancreatic cancer and may mediate drug
resistance to anticancer agents (Murray et al., 2013). Thus, cal-
cineurin and its downstream effectors may represent attractive
therapeutic targets in the treatment of pancreatitis and pancreatic
cancer.
AUTOPHAGY
Autophagy is a process of lysosome-mediated degradation and
recycling of cellular components, lipids, and proteins. The mate-
rials that are marked for degradation are sequestered into double
membrane autophagosomes which join with lysosomes to form
single membrane autolysosomes, and recycled products are sent
back to the cytoplasm. In the basal state this process helps to
remove protein aggregates and damaged organelles such as mito-
chondria and maintain cellular homeostasis (Gukovsky et al.,
2013). However, under oxidative stress, hypoxia, pathogen infec-
tion, or radiation exposure autophagy increases significantly to
protect the cell from further damage. Autophagy can become dys-
regulated, due to recurrent injury to pancreatic acinar cells, and
result in acinar cell vacuolization, trypsinogen activation, and cell
death (Figure 2) (Gukovsky et al., 2012, 2013).
Impairment of autophagy is a key feature of pancreatitis and
chiefly involves defective functional lysosomes. Accumulation
of large vacuoles in the acinar cell is one of the hallmark
characteristics of pancreatitis and many of these vacuoles are
FIGURE 2 | Autophagy and pancreatic disease. Autophagy is
responsible for clearance of aggregates of the sequestosome p62,
damaged mitochondria, apoptotic bodies, the inflammasome, and
reduces levels of reactive oxygen species (ROS). This limits injury and
inflammation in healthy cells and prevents neoplastic transformation and
initiation of PDAC. Therefore the role of autophagy is normally beneficial.
In tumor cells, however, autophagy promotes survival, enabling cancer to
resist hypoxia, nutrient depletion, and chemotherapy. Pancreatitis and
obesity lead to arrested autophagy resulting in elevated cellular injury
and inflammation. This can predispose to chronic disease and even
progression to PDAC.
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autolysosomes with poorly-degraded contents (Mareninova et al.,
2009). Furthermore, increased pancreatic levels of the autophagy
marker proteins Atg8/LC3-II accompany this vacuole formation
(Fortunato et al., 2009; Mareninova et al., 2009; Grasso et al.,
2011; Gukovskaya and Gukovsky, 2012). During pancreatitis,
autophagic efficiency and degradation of long-lived proteins are
reduced. Lysosomal hydrolytic activity is compromised and alter-
ations in lysosome-associated membrane proteins (LAMPs) are
seen (Fortunato et al., 2009; Mareninova et al., 2009; Gukovskaya
and Gukovsky, 2012; Gukovsky et al., 2012). In addition, levels of
the sequestosome, p62, a multi-purpose protein which mediates
autophagic clearance and can itself be degraded by autophagy, are
elevated. Collectively, these observations indicate loss of lysoso-
mal function and impairment of autophagic flux in AP. These
changes have been observed both in human disease and in exper-
imental models of AP (Fortunato et al., 2009; Mareninova et al.,
2009; Grasso et al., 2011; Gukovsky et al., 2011, 2012; Alirezaei
et al., 2012).
Deficient autophagy can also mediate pathologic accumula-
tion of active trypsin (Hashimoto et al., 2008; Mareninova et al.,
2009; Gukovskaya and Gukovsky, 2012). The respective roles
of the lysosomal hydrolases, cathepsins B and L were discussed
earlier in this review (section Role of Premature Trypsinogen
Activation); cathepsin B activates trypsinogen, forming trypsin,
whereas cathepsin L degrades both trypsin and trypsinogen.
Malfunctioning lysosomes in pancreatitis allow an imbalance
between these two cathepsins, resulting in less cathepsin L
and accumulation of active trypsin (Mareninova et al., 2009;
Gukovskaya and Gukovsky, 2012). In addition, disruption of
endogenous trypsin inhibitors, similar to that seen in cases of
CP, can abrogate autophagy (Ohmuraya et al., 2005; Romac
et al., 2010). When Spink-3 (the mouse ortholog of SPINK-1) is
compromised, autophagy is impaired and acinar cell vacuoliza-
tion and pancreatic degeneration occurs. Although impaired
autophagy has primarily been investigated in models of AP, the
latter evidence indicates a similar role for autophagy in CP.
Furthermore, a critical cellular function of efficient autophagy
is to limit inflammation; any compromise in autophagy
leads to persistent inflammation, which sets the stage for
development of CP.
Autophagy and inflammation
Defective autophagy is a key component in promoting persis-
tent inflammatory responses (Levine and Kroemer, 2008; Deretic,
2012). Accumulation of p62 through faulty autophagy can ulti-
mately lead to activation of the transcription factor NF-κB, a
critical mediator of inflammation (discussed further in section
NF-κB) (Ling et al., 2012;Moscat and Diaz-Meco, 2012). Arrested
autophagy also leads to elevations in reactive oxygen species
(ROS), due to lack of removal of damagedmitochondria. ROS can
activate inflammasomes, large intracellular multiprotein com-
plexes that play a central role in innate immunity (see section
Inflammasome) (Nathan and Ding, 2010; Green et al., 2011;
Strowig et al., 2012). In addition, inflammasomes are normally
eliminated through autophagy; lack of autophagy in pancreatitis
therefore maintains their presence in the cell and hence their par-
ticipation in the inflammatory process (Shi et al., 2012). Finally,
impaired autophagy disrupts clearance of apoptoticmaterial from
the acinar cell. This leads to secondary necrosis and the release
of damage-associated molecular pattern molecules (DAMPs),
which induce inflammation. Inflammation is a consistent theme
throughout the pancreatic disease continuum; if initial inflamma-
tory events subside, an acute episode results, however persistent
inflammation can lead to chronic disease. A more detailed dis-
cussion of inflammation and its multi-layered effects follows in
section Inflammation and Figure 3.
INFLAMMATION
NF-κB
NF-κB is a transcription factor which is involved in many cellular
signaling pathways involved in inflammation and stress-induced
FIGURE 3 | Inflammation and pancreatic disease. Insults lead to the
activation of NF-κB and inflammasomes. NF-κB activation leads to the
production of cytokines which, in turn, recruit immune cells and activate
Stat3. Neutrophils, macrophages and other immune cells infiltrate the
pancreas and produce more cytokines amplifying the inflammatory
response. Cytokines can lead to the activation of pancreatic stellate cells
which can, with repeated bouts of acute pancreatitis lead to fibrosis and
the development of chronic pancreatitis. Cytokines can activate oncogenic
Kras, a characteristic of nearly 90% of all pancreatic adenocarcinomas.
Chronic pancreatitis can also lead to the development of pancreatic cancer.
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responses (Senftleben and Karin, 2002). Upon activation NF-
κB component RelA/p50 is released from the inhibitor, IκB, and
translocates to the nucleus where it increases the expression of
pro-inflammatory mediators. Cytokines and adhesion molecules
attract additional immune cells and inflammation persists within
the pancreas (see section Cytokines and Pancreatitis) (Rakonczay
et al., 2008).
Levels of NF-κB rise independently of, but concurrently with,
trypsinogen activation (Gukovsky et al., 1998). Pathological rises
in calcium levels and activation of PKC isoforms have been
implicated in NF-κB activation. Decreased NF-κB activation has
been observed following treatment with calcium chelators and
experimental data from ethanol and cerulein models of pan-
creatitis has determined that NF-κB activation is mediated by
calcium/calcineurin and PKC pathways (Satoh et al., 2004; Muili
et al., 2012).
Ethanol increases the effect of CCK on NF-κB activa-
tion via PKC pathways demonstrating the role of alcohol in
sensitizing acinar cells to inflammatory responses and pancre-
atitis (Gukovskaya et al., 2004). The sensitizing effects of alco-
hol have also been observed in in vivo models of the disease;
alcohol-fed rats do not experience pancreatitis, but when treated
with lipopolysaccharide (LPS; an endotoxin in the cell wall of
Gram-negative bacteria) AP develops in the animals. Disease pro-
gression occurs leading to acinar cell atrophy and fibrosis, the
latter via activation of pancreatic stellate cells (PSCs) [see section
Pancreatic Stellate Cells (PSCs)] (Vonlaufen et al., 2011).
The above studies and others point to the detrimental role of
NF-κB in pancreatitis. However, some studies have determined
it to be beneficial (Gukovsky and Gukovskaya, 2013). For exam-
ple, transgenic mice with the deletion of IκB, an NF-κB inhibitor,
led to constitutive NF-κB activation but a decrease in cerulein-
stimulated pancreatitis was observed (Neuhofer et al., 2013).
In contrast, transgenic mice overexpressing IκB kinase (IKK2)
exhibited high levels of NF-κB activation and spontaneous AP
was observed. Over time these mice developed pancreatic dam-
age such as fibrosis, acinar cell atrophy, and inflammatory cell
infiltration indicating CP (Huang et al., 2013). One way to rec-
oncile these conflicting results is to point to NF-κB’s dual role
as promoter of both pro- and anti-inflammatory pathways. Early
events, as described above, show NF-κB as the key initiator to
the pro-inflammatory cascade of cytokines and other mediators.
However, NF-κB can reduce inflammation by limiting apopto-
sis, necroptosis, and the inflammasome (Algul et al., 2007; Gaiser
et al., 2011; Strowig et al., 2012). In addition, NF-κB activation
in inflammatory cells may be quite different, if not opposite, than
that observed in acinar cells (Treiber et al., 2011).
Persistent NF-κB activation was found in CP as well as 67%
of the pancreatic cancer specimens examined in one study (Wang
et al., 1999; Sah et al., 2013). Constitutive NF-κB activation pro-
motes low-grade inflammation creating an environment favor-
able to the development of cancer (Grivennikov et al., 2010).
Studies suppressing NF-κB activity have shown a decrease in
tumorigenesis or an induction in cytotoxicity in cancer cell lines
(Fujioka et al., 2003; Fabre et al., 2012).
NF-κB activation can also occur via a non-canonical (or alter-
native) pathway which differs from the canonical pathway in
its activation and downstream effectors (Sun, 2012). Namely,
in the alternative pathway NF-κB activation occurs with the
proteasome-mediated processing of the NF-κB component p100
to p52 which then translocates to the nucleus in combination
with RelB. Unlike the canonical pathway which depends on the
trimeric IKK complex for activation, the alternative pathway relies
on NF-κB-inducing kinase (NIK) and IKKα (Sun, 2011). In pan-
creatic cancer cells NF-κB activation has been shown to occur by
both pathways; in the alternative pathway, NIK is upregulated,
often due to the suppression of TNF-associated factor 2 (TRAF2)
(Nishina et al., 2009; Wharry et al., 2009). In a recent study,
NIK upregulation was observed in each of the 55 human PDAC
samples examined and 69% of the samples showed decreased
expression of the NIK inhibitor, TRAF2 (Doppler et al., 2013).
NF-κB and its effectors have emerged as targets for the devel-
opment of potential therapies to treat CP and pancreatic cancer.
Examples include anti-inflammatory drugs, polyphenols, and
proteasomal inhibitors (Carbone and Melisi, 2012; Aravindan
et al., 2013; Doppler et al., 2013). Alternative pathway compo-
nents such as NIK and TRAF2 are key proteins and may prove
favorable as targets for therapies. Therapies trying to induce
apoptosis in cancer cells are often stymied by high levels of NF-κB
limiting apoptosis. To surmount this, therapies are being tested
using NF-κB inhibitors, such as proteasomal inhibitors like borte-
zomib in combination with apoptotic drugs such as gemcitabine
(Ahn et al., 2012; Walsby et al., 2012; Salem et al., 2013).
Inflammasome
The inflammasome is a large multi-protein complex concerned
with detection of pathogen- and damage-associated molecular
patterns (PAMPS and DAMPS) which arise during insult or
injury to the pancreas. A typical inflammasome consists of a
sensor or scaffolding protein such as a nucleotide oligomeriza-
tion domain leucine-rich repeat-containing receptor (NLR), an
adaptor protein designated ASC, and pro-caspase-1 (Drexler and
Yazdi, 2013). During AP, pancreatic acinar cell injury and necrosis
causes release of DAMPS, including nuclear DNA, mitochon-
drial DNA and ATP. Resident macrophages within the pancreas
detect these DAMPs via (i) Toll-like receptor-9 (TLR-9) which
induces NFkB activation and pro-IL-1β transcription and (ii)
plasma membrane purinergic receptor P2X7, which mediates IL-
1βmaturation through inflammasomal components Nlrp3-ASC.
Subsequent generation of IL-1β results in further cytokine pro-
duction, recruitment of immune cells, and apoptosis (Hoque
et al., 2011).
The role of the inflammasome in the pathogenesis of acute
alcoholic pancreatitis has also been explored recently (Gu et al.,
2013). In alcohol-fed rats, treated with lipopolysaccharide (LPS),
pancreatic acinar cells had enhanced expression of cytokines
and chemokines, including the inflammasome-associated fac-
tors IL-18 and caspase-1. Furthermore, inflammasome mediated
responses were found to be initiated through TLR4-signaling.
Similar results were observed in acinar cells derived from patients
with acute/recurrent pancreatitis.
The inflammasome thus has a central role in promoting
chronic inflammation in pancreatitis but its contribution to pan-
creatic cancer remains largely unexplored. Generation of IL-1β
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and IL-18 may be the linking factor between inflammation and
tumor initiation/progression although current understanding is
limited (Drexler and Yazdi, 2013). In terms of treatment for
pancreatitis, targets in the inflammasome pathway merit inves-
tigation, although the implication for pancreatic cancer therapy
is less clear.
Cytokines and pancreatitis
In the early stages of AP, NF-κB (section NF-κB), and other tran-
scription factors such as activator protein-1 (AP-1) and nuclear
factor of activated T-cells (NFAT) are triggered resulting in the
production and release of cytokines from the acinar cell. Immune
cells such as neutrophils, macrophages, monocytes, and lympho-
cytes are recruited to the pancreas where they, in turn, produce
and secrete additional cytokines resulting in an amplification of
the inflammatory response. Key cytokines observed in serum and
the pancreas during AP, include the interleukins IL-1β, IL-6, IL-
8, as well as tumor necrosis factor (TNF-α) and soluble receptor
for tumor necrosis factor (sTNFr); furthermore, serum levels cor-
relate with disease severity (Mayer et al., 2000; Fisic et al., 2013).
Anti-inflammatory mediators such as interleukins IL-10, IL-11,
IL-22, TNF-α receptors, and IL-1 receptor antagonist (IL-1ra) are
produced in an effort to limit the inflammatory response; IL-10
and IL-22 have been shown to reduce AP in experimental animal
models (Feng et al., 2012; Koike et al., 2012; Xue et al., 2012; Fisic
et al., 2013).
Cytokines released during AP appear to also have roles in CP.
In contrast to its beneficial role in AP, IL-10 has been shown to
be instrumental in the development of CP in an experimental
animal model (Gu et al., 2009). Furthermore, cytokines TGF-β,
TNF-α, IL-1, IL-6, and IL-10 have been shown to activate pan-
creatic stellate cells which could either result in tissue repair or
the development of fibrosis [see section Pancreatic Stellate Cells
(PSCs)] (Apte et al., 1999; Mews et al., 2002).
Therapies for AP currently under study aim to inhibit pro-
inflammatory pathways, such as TNF-α, with neutralizing anti-
bodies, or up-regulate anti-inflammatory cytokines such as IL-10
or IL-22 (Feng et al., 2012; Xue et al., 2012; Sendler et al., 2013).
Elevation of anti-inflammatory cytokines as a therapy should be
approached with caution though, as up-regulation of cytokines
that reduce AP might also predispose to CP. Further study of
these pathways is required to resolve these complex issues, prior
to development of suitable therapies.
STAT3 and pancreatic cancer
Inflammation has been shown to be a key driver of pancreatic
cancer (Guerra et al., 2011; Yadav and Lowenfels, 2013). Immune
cells recruited to the pancreas and pancreatic stellate cells together
secrete a host of cytokines, growth factors and matrix modify-
ing enzymes that create a microenvironment favorable to PanIN
development and progression (Steele et al., 2013). Signal trans-
ducer and activator of transcription 3 (Stat3), a transcription
factor activated by cytokines such as IL-6 and growth factors such
as epidermal growth factor (EGF) is a key mediator of inflam-
mation (Grivennikov et al., 2010). Constitutively active Stat3 has
been observed in 30–100% of human pancreatic adenocarcinoma
samples examined (Scholz et al., 2003). Stat3 has also been shown
to be required for the activation and progression of PDAC (Scholz
et al., 2003; Corcoran et al., 2011; Fukuda et al., 2011; Lesina et al.,
2011). Interestingly, there is evidence for cross-talk between Stat3
and NF-κB: Stat3 promotes constitutively high levels of NF-κB
while NF-κB, in turn, may regulate Stat3 activation by recruiting
immune cells that secrete Stat3-activating cytokines (Bollrath and
Greten, 2009; Lee et al., 2009; Grivennikov and Karin, 2010).
Like NF-κB, Stat3 is an attractive target for therapies treating
pancreatic cancer. Inhibitors of a Stat3 kinase, Jak2, have reduced
solid tumor growth in animal models (Hedvat et al., 2009). Two
triterpenoids under study in animal models are Stat3 and NF-
κB inhibitors (Liby et al., 2010). Such compounds may also lend
themselves to be used in combination therapies with other drugs
such as gemcitabine.
COX-2 overexpression
The enzymes cyclooxygenase 1 and 2 (COX-1 and 2) are impor-
tant rate limiting factors in prostaglandin production. Whereas
COX-1 is constitutively expressed, there is very little COX-2
immunoreactivity in normal pancreatic acinar cells. However,
during inflammation COX-2 is upregulated and in CP it is over-
expressed in acinar, islet, and ductal cells. The presence of COX-2
in ductal cells points toward its role in modulating growth factors
and cytokines from ductal cells in fibrosis and inflammatory path-
ways (Eibl et al., 2004). COX-2 has been linked to development
of pancreatic dysplasia and PDAC and may form a potential link
between CP and subsequent development of pancreatic cancer.
Elevated COX-2 has been associated with pancreatic cancer cell
proliferation (Sun et al., 2009) and tumor growth (Colby et al.,
2008; Mukherjee et al., 2009; Hill et al., 2012). Moreover, a recent
study has shown that a combination therapy, involving pharma-
cologic inhibitors of COX-2 and histone deacetylases (HDAC),
a family of enzymes that regulate paramount cellular activities,
results in a complete inhibition of tumor growth.
HEAT SHOCK PROTEINS
Heat shock proteins (Hsp) are a family of survival proteins. Their
function in AP has often been considered protective although the
opposite is true in pancreatic cancer; they largely account for the
continued persistence of pancreatic tumors (Bhagat et al., 2002;
Banerjee et al., 2013). Triptolide is a naturally derived compound,
and its water-soluble pro-drug, Minnelide, have been shown to
down-regulate expression of Hsp 70 in pancreatic cancer cells,
resulting in cell death (Banerjee et al., 2013). This occurs via
decreased glycosylation of the transcription factor Sp1, and sub-
sequent down-regulation of pro-survival pathways like NF-κB.
Inhibition of Hsp70 and ultimately cell death follows. Given the
efficacy of this drug in preclinical trials, Minnelide studies have
now moved to Phase I clinical trials.
PANCREATIC STELLATE CELLS (PSCs)
Pancreatic stellate cells (PSCs) play an essential role in pancre-
atic fibrosis in CP and pancreatic cancer. These star-shaped cells
were first described in 1998 by two independent groups and since
then they have been extensively studied (Apte et al., 1998; Bachem
et al., 1998). Stellate cells lie in a quiescent state in periaci-
nar, perivascular, and periductal areas and store Vitamin-A lipid
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droplets in the cytoplasm (Apte et al., 1998). During pancreatic
injury, acinar cells, inflammatory cells, platelets, and endothelial
cells produce cytokines and growth factors such as transform-
ing growth factor beta (TGF-β) TNF-α, IL-1, IL-6, and activin
A which activate PSCs in a paracrine manner. PSCs also pro-
duce a range of growth factors and cytokines themselves and
could be activated in an autocrine manner. Upon activation PSCs
start expressing α-Smooth muscle actin (α-SMA), with a myofi-
broblast like phenotype, synthesizing excess extracellular matrix
components (ECM) such as collagen-1 and fibronectin (Omary
et al., 2007; Vonlaufen et al., 2008; Masamune and Shimosegawa,
2009; Masamune et al., 2009; Erkan et al., 2012a). In addition to
their pivotal role in fibrogenesis, PSCs synthesize matrix degrada-
tion enzymes like matrix metalloproteinases (MMPs) and their
inhibitors (tissue inhibitors of metalloproteinases or TIMPS)
(Phillips et al., 2003) that remodel the pancreatic parenchyma
(Yokota et al., 2002; Omary et al., 2007). Therefore PSCs may
play a role in maintenance of pancreatic architecture through
regulation of ECM turnover.
PSCs interact with, and may regulate, other pancreatic cell
types such as acinar cells and cancer cells. CCK has been shown
to initiate acetylcholine release from PSCs which subsequently
stimulates exocrine functions in acinar cells (Phillips et al., 2010).
These findings suggest a novel role for PSCs in physiological reg-
ulation of acinar cells. Whether such an interaction can initiate
pathological responses such as those observed in AP, remains
to be determined. It has also been reported that PSCs inter-
act with cancer cells and promote cancer progression through
multiple mechanisms including elevated proliferation, migra-
tion and metastasis (Bachem et al., 2005; Hwang et al., 2008;
Vonlaufen et al., 2008; Xu et al., 2010; Mantoni et al., 2011;
Erkan et al., 2012a,b). PSCs have been shown to induce epithe-
lial to mesenchymal transition (EMT) in pancreatic cancer cells.
EMT is a critical process in cancer progression, which allows a
polarized epithelial cell to assume a mesenchymal phenotype,
enabling it to acquire invasive andmetastatic properties and resis-
tance to apoptosis and therapies. Furthermore, recent studies
have shown that PSCs can augment stem cell-like phenotypes
in pancreatic cancer cells, enhancing tumorigenicity (Hamada
et al., 2012). Interactions between PSCs and other pancreatic cell
types therefore appear to be an essential component of pancre-
atic regulation and disease development. Further research on the
role of PSCs in development of pancreatitis and pancreatic can-
cer is required, given the emerging multi-functional roles these
cells play.
Kras
Kras is a guanine nucleotide binding protein and individual Kras
proteins act as binary molecular “switches” to activate a range
of important cellular signaling pathways. Kras can bind either
guanosine triphosphate (GTP) or guanosine diphosphate (GDP).
When occupied by GDP, Kras does not activate downstream sig-
naling pathways and is effectively “switched off.” Extracellular
signals coming from the environment in the form of growth
factors, cytokines, damage molecules (DAMPs), hormones, or
other molecules activate Kras. These molecules indirectly inter-
act with guanine nucleotide exchange factors (GEFs), replacing
GDP for GTP and switching Kras “on.” The active Kras sub-
sequently interacts with a wide range of downstream signaling
pathways including STAT3, NFκB, COX-2, and Scr. Some of these
pathways can generate signals, such as inflammatory mediators
that further activate Kras through positive feedback. Normal Kras
is rapidly inactivated by GTPase-activating proteins (GAPs) that
help hydrolyze GTP to GDP. Although individual Kras molecules
may act as a “binary switch,” populations of Kras proteins have
varying degrees of activity; at the cellular level, Kras is never truly
“on or off.” It is the number of active Kras proteins which define
the level of the resulting downstream signals. However, specific
point mutations in Kras, particularly those that affect Kras-GAP
interactions, limit GTP hydrolysis resulting in sustained activ-
ity for Kras. Such pathological responses can ultimately lead to
cancer.
Oncogenic Kras was first linked to pancreatic cancer over 20
years ago. The most common mutation in the majority of pan-
creatic tumors was identified as KrasG12D (Almoguera et al., 1988;
Smit et al., 1988). Development of genetic mouse models with
this mutation enabled researchers to learn more about pancre-
atic cancer development, although these models were found to
have limitations (Di Magliano and Logsdon, 2013). The mouse
models do not exactly match human disease; oncogenic Kras is
expressed in all pancreatic cells in mice, unlike pancreatic tumors
in humans. A combination of approaches, including the use of
human pancreatic cancer cell lines, primary human cultures and
human xenograft tumors in mice has yielded a broader view of
disease mechanisms.
Mouse models have been used to demonstrate how cellular
changes induced during pancreatitis, may actually lead to can-
cer progression in the presence of a Kras mutation. Induction of
AP with the CCK ortholog cerulein in wild-type mice leads to
acinar cell damage, infiltration of immune cells, and edema; the
level of damage peaking within a 24 h period. Tissue repair rapidly
occurs, and normal pancreatic histology is restored within 1 week.
In contrast, pancreata from mice with a Kras mutation (the KC
and iKras∗ models) fail to undergo tissue repair after cerulein
treatment (Morris et al., 2010; Collins et al., 2012a). In these mice,
acinar to ductal metaplasia progresses forming dysplastic ductal
structures, surrounded by extensive fibrosis, within 1 week. After
3 weeks, the majority of ductal structures exhibit characteristics
of PanINs. With time, higher-grade PanIN lesions populate the
pancreas resulting in development of carcinoma.
Merely the presence of a mutant copy of Kras may not be
entirely sufficient for development of pancreatic cancer. It is
widely thought that a threshold level of mutant Kras activity
must be reached for cancer progression to occur (Di Magliano
and Logsdon, 2013). In addition, sustained Kras activity may lead
to cellular stress which could result in apoptosis or senescence.
Factors which allow the cells to overcome the senescence barrier
such as inflammation or loss of tumor suppressor genes such as
p16 or p53may allow transformation to cancerous cells. In mouse
models of oncogenic Kras, pancreatic lesions rarely progress to
carcinoma unless additional mutations are introduced. Tumor
suppressors such as p53 and p16 are spontaneously lost at dif-
ferent rates, depending on levels of inflammation and/or Kras
activity. KC mice express endogenous levels of oncogenic Kras,
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and the tumor suppressor p53 has a tendency to be mutated or
lost in the later stages of tumor development (Hingorani et al.,
2003). In contrast, mice engineered to express high levels of onco-
genic Kras in pancreatic cells (Elastase- CreER;cLGL-KrasG12D,
or LGL model), rapidly lose p16 (Ji et al., 2009). These observa-
tions are consistent with those seen in patients, whereby pancre-
atic adenocarcinoma does not occur without the accumulation of
multiple genetic alterations, potentially over the course of many
years (Yachida et al., 2010). Loss, inactivation, or mutation of a
range of tumor suppressors (e.g., Tp53 and p16) is commonly
detected in human pancreatic tumors.
Onogenic Kras activation mediates many downstream cel-
lular targets including RAF-mitogen activated protein kinase,
Phosphoinositide-3-kinase (PI3K) and RalGDS pathways. The
P13-kinase-AKT pathway can play an important role in cell
survival and malignant transformation and is Ras dependent
(Fernandez-Medarde and Santos, 2011). It has been shown
that Kras plays a role in activation of the Hedgehog pathway.
Inhibition of the Hedgehog pathway dramatically decreases pro-
liferation of pancreatic cancer cells due to its impact on the cell
cycle regulators, Cyclin D1, N-myc, and Wnt proteins (Morton
et al., 2007). Since both Notch and Hedgehog pathways are
not activated in normal pancreas, it is postulated that there
is a link between their activation and molecular and genetic
alterations that occur during repetitive cell damage and repair
processes.
A more detailed view of the critical role played by Kras in
pancreatic disease is beyond the scope of this current review.
Kras is an integral player in pancreatic disease progression and
may play a role in transition of pancreatitis to pancreatic cancer.
Cellular processes involved in pancreatitis, such as inflamma-
tion and autophagy, may interact with Kras and its downstream
pathways, resulting in pancreatic lesions and PDAC development.
The interplay of Kras with autophagy will be discussed further
in the next section. Finally, in conjunction with other genetic
mutations, Kras can facilitate progression to pancreatic cancer.
In terms of therapy for pancreatic cancer, Kras is an attractive
target. In mouse models, inactivation of oncogenic Kras results
in tumor regression and the animals remain healthy over time
with no signs of relapse (Collins et al., 2012a,b; Ying et al., 2012).
Thus development of effective inhibitors for Kras, or targeting its
downstream effectors such as the kinase Akt or MAP Kinase may
be the direction to go in terms of drug development.
AUTOPHAGY AND DEVELOPMENT OF PANCREATIC CANCER
Earlier in this review, the role of autophagy in development of
acute and CP was discussed. Autophagy also plays a complex part
in the development of pancreatic cancer, with reports indicating
both pro-tumorigenic and tumor-suppressive roles (Liang et al.,
1999; Yue et al., 2003; Levine and Kroemer, 2008; Guo et al.,
2011, 2013; Takamura et al., 2011; Wei et al., 2011; Yang et al.,
2011; Aghajan et al., 2012; Mah and Ryan, 2012; White, 2012).
PDAC cells have higher basal levels of autophagy than most other
types of tumor cells, facilitating their survival under stressful con-
ditions including nutrient deprivation, hypoxia, metabolic stress
and chemotherapy (Aghajan et al., 2012). As the tumor environ-
ment is hypoxic, autophagy is often induced by hypoxia-inducible
factor-α signaling, or adenosine monophosphate activated pro-
tein kinase (AMPK), the latter also being associated with pan-
creatitis (Shugrue et al., 2012). Elevated levels of autophagy in
PDAC cells are critical in removal of ROS, preventing DNA dam-
age and maintaining energy homeostasis, thus optimizing PDAC
cell survival and proliferation (Yang and Kimmelman, 2011).
In contrast, in non-transformed epithelial cells, PDAC initia-
tion is suppressed by autophagy. ROS production, genomic dam-
age, inflammation, and cellular injury are limited. In addition,
oncogenic aggregates of p62 are eliminated. However, as discussed
earlier, when impairment of autophagy and lysosomal dysfunc-
tion occurs pancreatitis is initiated. This can lead to chronic
pancreatic injury and compensatory proliferation of stem cells,
resulting in ductal metaplasia and regenerative responses which
contribute to tumorigenesis. Pathways such as Notch, Hedgehog,
andWnt-β catenin are activated in pancreatic tissues in CP during
the regenerative response and dysregulation of these pathways has
been attributed to pancreatic tumorigenesis (Bhanot and Moller,
2009).
Several clinical trials are currently using inhibitors of
autophagy, such as hydroxychloroquine (which halts lysosomal
acidification and autophagosome degradation), in the treatment
of PDAC (Amaravadi et al., 2011). Inhibition of autophagy has
been shown to retard growth of pancreatic xenograft tumors in
mice, and development of tumors inmice with pancreata contain-
ing oncogenic Kras (Yang et al., 2011). However, a recent study
demonstrated that treatment of PDAC maybe more complex
(Rosenfeldt et al., 2013). In a humanized genetically-modified
mouse model of PDAC, the role of autophagy in tumor devel-
opment was found to be inherently linked to the status of the
tumor suppressor p53. Kras mice developed a small number of
pre-cancerous lesions that became PDAC over time. However, it
was found that mice also lacking the essential autophagy genes
Atg5 orAtg7 accumulated low grade pre-malignant PanIN lesions,
which did not progress to high grade PanINs and PDAC. In
contrast, in mice lacking Kras and p53, a loss of autophagy no
longer blocked tumor progression, but actually accelerated the
onset of tumors and increased uptake of glucose to fuel tumor
growth. Furthermore, this study showed that treatment of the
mice with hydroxychloroquine actually accelerated tumor forma-
tion in mice with onogenic Kras but lacking p53. Thus the role
of autophagy in pancreatic cancer is extremely complex and care
needs to be taken when designing appropriate therapies.
OBESITY AND PANCREATIC DISEASE
Obesity is a major health problem worldwide and leads to
increases in risk for cardiovascular disease, stroke, and a vari-
ety of cancers (Hotamisligil and Erbay, 2008; Osborn and
Olefsky, 2012). Obesity can result in low grade chronic inflam-
mation which renders patients vulnerable to these diseases,
although the underlying cellular mechanisms between obe-
sity and inflammation remain vague (Weisberg et al., 2003;
Hotamisligil and Erbay, 2008; Johnson et al., 2012; Osborn
and Olefsky, 2012). Obesity is known to increase the num-
ber of CD8+ T-cells and decrease T-regulatory cells, promoting
recruitment of macrophages (Johnson et al., 2012). Elevated
levels of inflammatory mediators such as TNF-α, IL-1β, IL-6,
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and IL-18 are seen within adipose tissue and also systemically
through inflammasome activation in macrophages (Stienstra
et al., 2011). Inflammatory mediators secreted by macrophages
further augment general inflammation. In addition, levels of
the pro-inflammatory hormone leptin are increased by obesity
and decreases in adiponectin, its anti-inflammatory counterpart,
are observed. Obesity, or a high fat diet (HFD), can also affect
autophagy, increasing ER stress and inflammation (Yang et al.,
2010; Hasnain et al., 2012). Obesity inhibits autophagy by acti-
vating Akt and mTOR signaling pathways, and down-regulating
autophagic genes such as Ulk1/Atg1, Atg5, Atg6/Beclin 1.
Obesity has been linked to increased risk and severity of pan-
creatitis (Frossard et al., 2009; Navina et al., 2011). Deletion
of leptin (ob/ob) or the leptin receptor (db/db), or administra-
tion of an HFD, in mice caused obesity and increased sever-
ity of pancreatitis. Following induction of pancreatitis with
cerulein, levels of pancreatic IL-1β, IL-6, CCL2/MCP-1, and
neutrophil infiltration were much greater in ob/ob and db/db
mice compared to their lean littermates (Zyromski et al., 2008).
Furthermore, in a model of AP induced by a combination
of IL-12 and IL-18, severe disease occurred in ob/ob mice
compared to wild type mice (Sennello et al., 2008). Finally,
in a model of taurocholate-induced pancreatitis TNF-α lev-
els increased while IL-10 was reduced, resulting in necrosis of
adipose tissue (Franco-Pons et al., 2010). Thus obesity-related
inflammatorymediators appear to play a pivotal role in severity of
pancreatitis.
Obesity and HFD have further been identified as prominent
risk factors for pancreatic cancer (Wiseman, 2008). Consumption
of an HFD in mice with oncogenic Kras expression increased
PanIN formation, fibrosis, inflammation, and PDAC, resulting in
reduced survival (Philip et al., 2013). In contrast, control mice
lacking Kras expression and fed with HFD, or Kras-expressing
mice fed a control diet (CD), showed minimal pancreatic pathol-
ogy. This model underscores the risk posed by an HFD in humans
that express pancreatic oncogenic Kras. Activity of Kras and its
downstream effectors such as COX-2 and phospho-ERK are ele-
vated. Infiltration of macrophages into the stroma and activation
of quiescent PSCs producing α-SMA and collagen I also occurs.
COX-2 forms a positive feed-forward loop thus maintaining Kras
activity and further augments inflammation, fibrosis, and recruit-
ment of inflammatory mediators to the pancreas. This ultimately
leads to development of PanINs and PDAC. Given that many
healthy individuals express oncogenic Kras, consumption of HFD
could put them at greater risk of developing PDAC. Consuming
a reduced fat diet and ingestion of COX-2 inhibitors could limit
pancreatic inflammation and fibrosis and may prevent formation
of PanINs and progression to PDAC.
CONCLUSION
Although our knowledge of underlying mechanisms of pan-
creatitis and pancreatic cancer have advanced in the past few
years much remains unknown. Recent studies have strongly
implicated smoking, alcohol, and obesity as common etiolog-
ical factors in pancreatitis-to-cancer pathways. At the cellular
level, aberrant zymogen activation, particularly through muta-
tions in trypsinogen, can lead to repeat bouts of AP. This can
result in low grade inflammation, autophagy, stellate cell activa-
tion, and fibrosis, culminating in chronic disease. Furthermore,
oncogenic Kras mutations and modifications of tumor sup-
pressor genes (p16 and p53) may all contribute to progression
from CP to PDAC (Figure 1). Development of multiple drugs
that target various aspects of this complex tapestry of cellular
pathways will be paramount in halting disease initiation and
progression.
ACKNOWLEDGMENTS
The authors would like to acknowledge Fred Gorelick, MD for
a critical review of this manuscript and the following funding
source: NIH R21 AA020847-01 to Edwin C. Thrower.
REFERENCES
Aghajan, M., Li, N., and Karin, M. (2012). Obesity, autophagy and the pathogenesis
of liver and pancreatic cancers. J. Gastroenterol. Hepatol. 27(Suppl. 2), 10–14.
doi: 10.1111/j.1440-1746.2011.07008.x
Ahn, D. W., Seo, J. K., Lee, S. H., Hwang, J. H., Lee, J. K., Ryu, J. K.,
et al. (2012). Enhanced antitumor effect of combination therapy with gemc-
itabine and guggulsterone in pancreatic cancer. Pancreas 41, 1048–1057. doi:
10.1097/MPA.0b013e318249d62e
Algul, H., Treiber, M., Lesina, M., Nakhai, H., Saur, D., Geisler, F., et al.
(2007). Pancreas-specific RelA/p65 truncation increases susceptibility of acini
to inflammation-associated cell death following cerulein pancreatitis. J. Clin.
Invest. 117, 1490–1501. doi: 10.1172/JCI29882
Alirezaei, M., Flynn, C. T., and Whitton, J. L. (2012). Interactions between
enteroviruses and autophagy in vivo. Autophagy 8, 973–975. doi:
10.4161/auto.20160
Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., and Perucho,
M. (1988). Most human carcinomas of the exocrine pancreas contain mutant
c-K-ras genes. Cell 53, 549–554. doi: 10.1016/0092-8674(88)90571-5
Amaravadi, R. K., Lippincott-Schwartz, J., Yin, X. M., Weiss, W. A., Takebe,
N., Timmer, W., et al. (2011). Principles and current strategies for target-
ing autophagy for cancer treatment. Clin. Cancer Res. 17, 654–666. doi:
10.1158/1078-0432.CCR-10-2634
Apte,M. V., Haber, P. S., Applegate, T. L., Norton, I. D.,McCaughan, G.W., Korsten,
M. A., et al. (1998). Periacinar stellate shaped cells in rat pancreas: identification,
isolation, and culture. Gut 43, 128–133. doi: 10.1136/gut.43.1.128
Apte, M. V., Haber, P. S., Darby, S. J., Rodgers, S. C., McCaughan, G. W., Korsten,
M. A., et al. (1999). Pancreatic stellate cells are activated by proinflamma-
tory cytokines: implications for pancreatic fibrogenesis. Gut 44, 534–541. doi:
10.1136/gut.44.4.534
Aravindan, S., Delma, C. R., Thirugnanasambandan, S. S., Herman, T. S., and
Aravindan, N. (2013). Anti-pancreatic cancer deliverables from sea: first-hand
evidence on the efficacy, molecular targets and mode of action for multifar-
ious polyphenols from five different brown-algae. PLoS ONE 8:e61977. doi:
10.1371/journal.pone.0061977
Bachem, M. G., Schneider, E., Gross, H., Weidenbach, H., Schmid, R. M.,
Menke, A., et al. (1998). Identification, culture, and characterization of pan-
creatic stellate cells in rats and humans. Gastroenterology 115, 421–432. doi:
10.1016/S0016-5085(98)70209-4
Bachem, M. G., Schunemann, M., Ramadani, M., Siech, M., Beger, H., Buck, A.,
et al. (2005). Pancreatic carcinoma cells induce fibrosis by stimulating prolifer-
ation and matrix synthesis of stellate cells. Gastroenterology 128, 907–921. doi:
10.1053/j.gastro.2004.12.036
Banerjee, S., Sangwan, V., McGinn, O., Chugh, R., Dudeja, V., Vickers, S. M.,
et al. (2013). Triptolide-induced cell death in pancreatic cancer is mediated
by O-GlcNAc modification of transcription factor Sp1. J. Biol. Chem. 288,
33927–33938. doi: 10.1074/jbc.M113.500983
Bayliss, W. M., and Starling, E. H. (1902). The mechanism of pancreatic secretion.
J. Physiol. 28, 325–353.
Beer, S., Zhou, J., Szabo, A., Keiles, S., Chandak, G. R., Witt, H., et al. (2013).
Comprehensive functional analysis of chymotrypsin C (CTRC) variants reveals
distinct loss-of-function mechanisms associated with pancreatitis risk. Gut 62,
1616–1624. doi: 10.1136/gutjnl-2012-303090
Frontiers in Physiology | Gastrointestinal Sciences January 2014 | Volume 4 | Article 415 | 10
Kolodecik et al. Pancreatitis to cancer pathways
Bhagat, L., Singh, V. P., Song, A. M., Van Acker, G. J., Agrawal, S., Steer, M. L., et al.
(2002). Thermal stress-induced HSP70 mediates protection against intrapan-
creatic trypsinogen activation and acute pancreatitis in rats. Gastroenterology
122, 156–165. doi: 10.1053/gast.2002.30314
Bhanot, U. K., and Moller, P. (2009). Mechanisms of parenchymal injury and
signaling pathways in ectatic ducts of chronic pancreatitis: implications for pan-
creatic carcinogenesis. Lab. Invest. 89, 489–497. doi: 10.1038/labinvest.2009.19
Bhoomagoud, M., Jung, T., Atladottir, J., Kolodecik, T. R., Shugrue, C., Chaudhuri,
A., et al. (2009). Reducing extracellular pH sensitizes the acinar cell to
secretagogue-induced pancreatitis responses in rats. Gastroenterology 137,
1083–1092. doi: 10.1053/j.gastro.2009.05.041
Bollrath, J., and Greten, F. R. (2009). IKK/NF-kappaB and STAT3 pathways: central
signalling hubs in inflammation-mediated tumour promotion and metastasis.
EMBO Rep. 10, 1314–1319. doi: 10.1038/embor.2009.243
Cancela, J. M., Van Coppenolle, F., Galione, A., Tepikin, A. V., and Petersen, O. H.
(2002). Transformation of local Ca2+ spikes to global Ca2+ transients: the com-
binatorial roles of multiple Ca2+ releasing messengers. EMBO J. 21, 909–919.
doi: 10.1093/emboj/21.5.909
Carbone, C., and Melisi, D. (2012). NF-kappaB as a target for pancre-
atic cancer therapy. Expert Opin. Ther. Targets 16(Suppl. 2), S1–S10. doi:
10.1517/14728222.2011.645806
Chen, J. M., and Ferec, C. (2009). Chronic pancreatitis: genetics and pathogenesis.
Annu. Rev. Genomics Hum. Genet. 10, 63–87. doi: 10.1146/annurev-genom-
082908-150009
Chen, J. M., and Ferec, C. (2012). Genetics and pathogenesis of chronic pan-
creatitis: the 2012 update. Clin. Res. Hepatol. Gastroenterol. 36, 334–340. doi:
10.1016/j.clinre.2012.05.003
Choudari, C. P., Lehman, G. A., and Sherman, S. (1999). Pancreatitis and cystic
fibrosis genemutations.Gastroenterol. Clin. North Am. 28, 543–549, vii–viii. doi:
10.1016/S0889-8553(05)70072-8
Colby, J. K., Klein, R. D., McArthur, M. J., Conti, C. J., Kiguchi, K., Kawamoto,
T., et al. (2008). Progressive metaplastic and dysplastic changes in mouse pan-
creas induced by cyclooxygenase-2 overexpression. Neoplasia 10, 782–796. doi:
10.1593/neo.08330
Collins, M. A., Bednar, F., Zhang, Y., Brisset, J. C., Galban, S., Galban, C. J., et al.
(2012a). Oncogenic Kras is required for both the initiation and maintenance of
pancreatic cancer in mice. J. Clin. Invest. 122, 639–653. doi: 10.1172/JCI59227
Collins, M. A., Brisset, J. C., Zhang, Y., Bednar, F., Pierre, J., Heist, K. A., et al.
(2012b). Metastatic pancreatic cancer is dependent on oncogenic Kras in mice.
PLoS ONE 7:e49707. doi: 10.1371/journal.pone.0049707
Corcoran, R. B., Contino, G., Deshpande, V., Tzatsos, A., Conrad, C., Benes,
C. H., et al. (2011). STAT3 plays a critical role in KRAS-induced pancre-
atic tumorigenesis. Cancer Res. 71, 5020–5029. doi: 10.1158/0008-5472.CAN-
11-0908
Cosen-Binker, L. I., Lam, P. P., Binker, M. G., Reeve, J., Pandol, S., and Gaisano, H.
Y. (2007). Alcohol/cholecystokinin-evoked pancreatic acinar basolateral exocy-
tosis is mediated by protein kinase C alpha phosphorylation of Munc18c. J. Biol.
Chem. 282, 13047–13058. doi: 10.1074/jbc.M611132200
Criddle, D. N., Murphy, J., Fistetto, G., Barrow, S., Tepikin, A. V., Neoptolemos,
J. P., et al. (2006). Fatty acid ethyl esters cause pancreatic calcium toxicity via
inositol trisphosphate receptors and loss of ATP synthesis.Gastroenterology 130,
781–793. doi: 10.1053/j.gastro.2005.12.031
Dawra, R., Sah, R. P., Dudeja, V., Rishi, L., Talukdar, R., Garg, P., et al. (2011).
Intra-acinar trypsinogen activation mediates early stages of pancreatic injury
but not inflammation in mice with acute pancreatitis. Gastroenterology 141,
2210–2217.e2212. doi: 10.1053/j.gastro.2011.08.033
Deretic, V. (2012). Autophagy: an emerging immunological paradigm. J. Immunol.
189, 15–20. doi: 10.4049/jimmunol.1102108
Di Magliano, M. P., and Logsdon, C. D. (2013). Roles for KRAS in pancreatic
tumor development and progression. Gastroenterology 144, 1220–1229. doi:
10.1053/j.gastro.2013.01.071
Doppler, H., Liou, G. Y., and Storz, P. (2013). Downregulation of TRAF2 mediates
NIK-induced pancreatic cancer cell proliferation and tumorigenicity. PLoS ONE
8:e53676. doi: 10.1371/journal.pone.0053676
Drexler, S. K., and Yazdi, A. S. (2013). Complex roles of inflammasomes in
carcinogenesis. Cancer J. 19, 468–472. doi: 10.1097/PPO.0000000000000004
Eibl, G., Reber, H. A., Hines, O. J., and Go, V. L. (2004). COX and PPAR: possible
interactions in pancreatic cancer. Pancreas 29, 247–253. doi: 10.1097/00006676-
200411000-00002
Erkan, M., Adler, G., Apte, M. V., Bachem, M. G., Buchholz, M., Detlefsen, S., et al.
(2012a). StellaTUM: current consensus and discussion on pancreatic stellate cell
research. Gut 61, 172–178. doi: 10.1136/gutjnl-2011-301220
Erkan, M., Hausmann, S., Michalski, C. W., Fingerle, A. A., Dobritz, M., Kleeff,
J., et al. (2012b). The role of stroma in pancreatic cancer: diagnostic and
therapeutic implications. Nat. Rev. Gastroenterol. Hepatol. 9, 454–467. doi:
10.1038/nrgastro.2012.115
Fabre, C., Mimura, N., Bobb, K., Kong, S. Y., Gorgun, G., Cirstea, D., et al. (2012).
Dual inhibition of canonical and noncanonical NF-kappaB pathways demon-
strates significant antitumor activities in multiple myeloma. Clin. Cancer Res.
18, 4669–4681. doi: 10.1158/1078-0432.CCR-12-0779
Feng, D., Park, O., Radaeva, S., Wang, H., Yin, S., Kong, X., et al. (2012).
Interleukin-22 ameliorates cerulein-induced pancreatitis in mice by inhibit-
ing the autophagic pathway. Int. J. Biol. Sci. 8, 249–257. doi: 10.7150/
ijbs.3967
Fernandez-Medarde, A., and Santos, E. (2011). Ras in cancer and developmental
diseases. Genes Cancer 2, 344–358. doi: 10.1177/1947601911411084
Figarella, C., Miszczuk-Jamska, B., and Barrett, A. J. (1988). Possible lysosomal
activation of pancreatic zymogens. Activation of both human trypsinogens by
cathepsin B and spontaneous acid. Activation of human trypsinogen 1. Biol.
Chem. Hoppe Seyler 369(Suppl.), 293–298.
Fisic, E., Poropat, G., Bilic-Zulle, L., Licul, V., Milic, S., and Stimac, D. (2013). The
role of IL-6, 8, and 10, sTNFr, CRP, and pancreatic elastase in the prediction
of systemic complications in patients with acute pancreatitis. Gastroenterol. Res.
Pract. 2013, 282645. doi: 10.1155/2013/282645
Fortunato, F., Burgers, H., Bergmann, F., Rieger, P., Buchler, M. W., Kroemer, G.,
et al. (2009). Impaired autolysosome formation correlates with Lamp-2 deple-
tion: role of apoptosis, autophagy, and necrosis in pancreatitis. Gastroenterology
137, 350–360, 360.e351–e355. doi: 10.1053/j.gastro.2009.04.003
Franco-Pons, N., Gea-Sorli, S., and Closa, D. (2010). Release of inflammatory
mediators by adipose tissue during acute pancreatitis. J. Pathol. 221, 175–182.
doi: 10.1002/path.2691
Frossard, J. L., Lescuyer, P., and Pastor, C. M. (2009). Experimental evidence of
obesity as a risk factor for severe acute pancreatitis. World J. Gastroenterol. 15,
5260–5265. doi: 10.3748/wjg.15.5260
Fujioka, S., Sclabas, G. M., Schmidt, C., Niu, J., Frederick, W. A., Dong, Q. G., et al.
(2003). Inhibition of constitutive NF-kappa B activity by I kappa B alphaM sup-
presses tumorigenesis. Oncogene 22, 1365–1370. doi: 10.1038/sj.onc.1206323
Fukuda, A., Wang, S. C., Morris, J. P. T., Folias, A. E., Liou, A., Kim, G. E.,
et al. (2011). Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma
initiation and progression. Cancer Cell 19, 441–455. doi: 10.1016/j.ccr.2011.
03.002
Gaiser, S., Daniluk, J., Liu, Y., Tsou, L., Chu, J., Lee, W., et al. (2011). Intracellular
activation of trypsinogen in transgenic mice induces acute but not chronic
pancreatitis. Gut 60, 1379–1388. doi: 10.1136/gut.2010.226175
Glitsch, M. D., Bakowski, D., and Parekh, A. B. (2002). Store-operated Ca2+
entry depends on mitochondrial Ca2+ uptake. EMBO J. 21, 6744–6754. doi:
10.1093/emboj/cdf675
Gopinathan, A., Denicola, G. M., Frese, K. K., Cook, N., Karreth, F. A., Mayerle,
J., et al. (2012). Cathepsin B promotes the progression of pancreatic ductal
adenocarcinoma in mice. Gut 61, 877–884. doi: 10.1136/gutjnl-2011-300850
Gorelick, F. S., and Matovcik, L. M. (1995). Lysosomal enzymes and pancreatitis.
Gastroenterology 109, 620–625. doi: 10.1016/0016-5085(95)90355-0
Grasso, D., Ropolo, A., Lo Re, A., Boggio, V., Molejon, M. I., Iovanna, J. L., et al.
(2011). Zymophagy, a novel selective autophagy pathway mediated by VMP1-
USP9x-p62, prevents pancreatic cell death. J. Biol. Chem. 286, 8308–8324. doi:
10.1074/jbc.M110.197301
Green, D. R., Galluzzi, L., and Kroemer, G. (2011). Mitochondria and the
autophagy-inflammation-cell death axis in organismal aging. Science 333,
1109–1112. doi: 10.1126/science.1201940
Grivennikov, S. I., Greten, F. R., and Karin, M. (2010). Immunity, inflammation,
and cancer. Cell 140, 883–899. doi: 10.1016/j.cell.2010.01.025
Grivennikov, S. I., and Karin, M. (2010). Dangerous liaisons: STAT3 and NF-
kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 21,
11–19. doi: 10.1016/j.cytogfr.2009.11.005
Gu, H., Werner, J., Bergmann, F., Whitcomb, D. C., Buchler, M. W., and Fortunato,
F. (2013). Necro-inflammatory response of pancreatic acinar cells in the
pathogenesis of acute alcoholic pancreatitis. Cell Death Dis. 4, e816. doi:
10.1038/cddis.2013.354
www.frontiersin.org January 2014 | Volume 4 | Article 415 | 11
Kolodecik et al. Pancreatitis to cancer pathways
Gu, R., Shampang, A., Reilly, A., Fisher, D., Glass, W., and Ramsingh, A. I.
(2009). IL-10 is pathogenic during the development of coxsackievirus B4-
induced chronic pancreatitis. Virology 395, 77–86. doi: 10.1016/j.virol.2009.
09.005
Guerra, C., Collado, M., Navas, C., Schuhmacher, A. J., Hernandez-Porras, I.,
Canamero, M., et al. (2011). Pancreatitis-induced inflammation contributes to
pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell 19,
728–739. doi: 10.1016/j.ccr.2011.05.011
Gukovskaya, A. S., and Gukovsky, I. (2012). Autophagy and pancreati-
tis. Am. J. Physiol. Gastrointest. Liver Physiol. 303, G993–G1003. doi:
10.1152/ajpgi.00122.2012
Gukovskaya, A. S., Hosseini, S., Satoh, A., Cheng, J. H., Nam, K. J., Gukovsky, I.,
et al. (2004). Ethanol differentially regulates NF-kappaB activation in pancre-
atic acinar cells through calcium and protein kinase C pathways. Am. J. Physiol.
Gastrointest. Liver Physiol. 286, G204–G213. doi: 10.1152/ajpgi.00088.2003
Gukovsky, I., and Gukovskaya, A. (2013). Nuclear factor-kappaB in pancreati-
tis: jack-of-all-trades, but which one is more important? Gastroenterology 144,
26–29. doi: 10.1053/j.gastro.2012.11.016
Gukovsky, I., Gukovskaya, A. S., Blinman, T. A., Zaninovic, V., and Pandol, S. J.
(1998). Early NF-κB activation is associated with hormone-induced pancreati-
tis. Am. J. Physiol. 275, G1402–G1414.
Gukovsky, I., Li, N., Todoric, J., Gukovskaya, A., and Karin, M. (2013).
Inflammation, autophagy, and obesity: common features in the pathogenesis
of pancreatitis and pancreatic cancer. Gastroenterology 144, 1199–1209. e1194.
doi: 10.1053/j.gastro.2013.02.007
Gukovsky, I., Pandol, S. J., and Gukovskaya, A. S. (2011). Organellar dysfunction
in the pathogenesis of pancreatitis. Antioxid. Redox Signal. 15, 2699–2710. doi:
10.1089/ars.2011.4068
Gukovsky, I., Pandol, S. J., Mareninova, O. A., Shalbueva, N., Jia, W., and
Gukovskaya, A. S. (2012). Impaired autophagy and organellar dysfunction in
pancreatitis. J. Gastroenterol. Hepatol. 27(Suppl. 2), 27–32. doi: 10.1111/j.1440-
1746.2011.07004.x
Guo, J. Y., Chen, H. Y., Mathew, R., Fan, J., Strohecker, A. M., Karsli-
Uzunbas, G., et al. (2011). Activated Ras requires autophagy to main-
tain oxidative metabolism and tumorigenesis. Genes Dev. 25, 460–470. doi:
10.1101/gad.2016311
Guo, J. Y., Karsli-Uzunbas, G., Mathew, R., Aisner, S. C., Kamphorst, J. J.,
Strohecker, A. M., et al. (2013). Autophagy suppresses progression of K-ras-
induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes
Dev. 27, 1447–1461. doi: 10.1101/gad.219642.113
Halangk, W., Lerch, M. M., Brandt-Nedelev, B., Roth, W., Ruthenbuerger, M.,
Reinheckel, T., et al. (2000). Role of cathepsin B in intracellular trypsinogen
activation and the onset of acute pancreatitis. J. Clin. Invest. 106, 773–781. doi:
10.1172/JCI9411
Hamada, S., Masamune, A., Takikawa, T., Suzuki, N., Kikuta, K., Hirota, M.,
et al. (2012). Pancreatic stellate cells enhance stem cell-like phenotypes in
pancreatic cancer cells. Biochem. Biophys. Res. Commun. 421, 349–354. doi:
10.1016/j.bbrc.2012.04.014
Hashimoto, D., Ohmuraya, M., Hirota, M., Yamamoto, A., Suyama, K., Ida, S.,
et al. (2008). Involvement of autophagy in trypsinogen activation within the
pancreatic acinar cells. J. Cell Biol. 181, 1065–1072. doi: 10.1083/jcb.200712156
Hasnain, S. Z., Lourie, R., Das, I., Chen, A. C., and McGuckin, M. A. (2012). The
interplay between endoplasmic reticulum stress and inflammation. Immunol.
Cell Biol. 90, 260–270. doi: 10.1038/icb.2011.112
Hedvat, M., Huszar, D., Herrmann, A., Gozgit, J. M., Schroeder, A., Sheehy, A., et al.
(2009). The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and onco-
genesis in solid tumors. Cancer Cell 16, 487–497. doi: 10.1016/j.ccr.2009.10.015
Hill, R., Li, Y., Tran, L. M., Dry, S., Calvopina, J. H., Garcia, A., et al. (2012). Cell
intrinsic role of COX-2 in pancreatic cancer development.Mol. Cancer Ther. 11,
2127–2137. doi: 10.1158/1535-7163.MCT-12-0342
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz,
M. A., et al. (2003). Preinvasive and invasive ductal pancreatic cancer and
its early detection in the mouse. Cancer Cell 4, 437–450. doi: 10.1016/S1535-
6108(03)00309-X
Hoque, R., Sohail, M., Malik, A., Sarwar, S., Luo, Y., Shah, A., et al. (2011). TLR9
and the NLRP3 inflammasome link acinar cell death with inflammation in acute
pancreatitis. Gastroenterology 141, 358–369. doi: 10.1053/j.gastro.2011.03.041
Hotamisligil, G. S., and Erbay, E. (2008). Nutrient sensing and inflammation in
metabolic diseases. Nat. Rev. Immunol. 8, 923–934. doi: 10.1038/nri2449
Howes, N., Lerch, M. M., Greenhalf, W., Stocken, D. D., Ellis, I., Simon, P., et al.
(2004). Clinical and genetic characteristics of hereditary pancreatitis in Europe.
Clin. Gastroenterol. Hepatol. 2, 252–261. doi: 10.1016/S1542-3565(04)00013-8
Huang, H., Liu, Y., Daniluk, J., Gaiser, S., Chu, J., Wang, H., et al. (2013). Activation
of nuclear factor-kappaB in acinar cells increases the severity of pancreatitis in
mice. Gastroenterology 144, 202–210. doi: 10.1053/j.gastro.2012.09.059
Husain, S. Z., Prasad, P., Grant, W. M., Kolodecik, T. R., Nathanson, M. H., and
Gorelick, F. S. (2005). The ryanodine receptor mediates early zymogen acti-
vation in pancreatitis. Proc. Natl. Acad. Sci. U.S.A. 102, 14386–14391. doi:
10.1073/pnas.0503215102
Hwang, R. F., Moore, T., Arumugam, T., Ramachandran, V., Amos, K. D., Rivera,
A., et al. (2008). Cancer-associated stromal fibroblasts promote pancreatic
tumor progression. Cancer Res. 68, 918–926. doi: 10.1158/0008-5472.CAN-07-
5714
Ji, B., Tsou, L., Wang, H., Gaiser, S., Chang, D. Z., Daniluk, J., et al. (2009). Ras
activity levels control the development of pancreatic diseases. Gastroenterology
137, 1072–1082, 1082.e1071–e1076. doi: 10.1053/j.gastro.2009.05.052
Jiang, G. Z., Cao, F. Y., Ren, G. P., Gao, D. L., Bhakta, V., Zhang, Y. H., et al. (2010).
PRSS3 promotes tumour growth and metastasis of human pancreatic cancer.
Gut 59, 1535–1544. doi: 10.1136/gut.2009.200105
Johnson, A. R., Milner, J. J., and Makowski, L. (2012). The inflammation high-
way: metabolism accelerates inflammatory traffic in obesity. Immunol. Rev. 249,
218–238. doi: 10.1111/j.1600-065X.2012.01151.x
Judak, L., Hegyi, P., Rakonczay, Z. Jr., Maleth, J., Gray, M. A., and Venglovecz,
V. (2013). Ethanol and its non-oxidative metabolites profoundly inhibit CFTR
function in pancreatic epithelial cells which is prevented by ATP supplementa-
tion. Pflugers Arch. doi: 10.1007/s00424-013-1333-x. [Epub ahead of print].
Jung, I. H., Jung, D. E., Park, Y. N., Song, S. Y., and Park, S. W. (2011). Aberrant
Hedgehog ligands induce progressive pancreatic fibrosis by paracrine activa-
tion of myofibroblasts and ductular cells in transgenic zebrafish. PLoS ONE
6:e27941. doi: 10.1371/journal.pone.0027941
Kim, M. S., Hong, J. H., Li, Q., Shin, D. M., Abramowitz, J., Birnbaumer, L.,
et al. (2009). Deletion of TRPC3 in mice reduces store-operated Ca2+ influx
and the severity of acute pancreatitis. Gastroenterology 137, 1509–1517. doi:
10.1053/j.gastro.2009.07.042
Kim, M. S., Lee, K. P., Yang, D., Shin, D. M., Abramowitz, J., Kiyonaka,
S., et al. (2011). Genetic and pharmacologic inhibition of the Ca2+
influx channel TRPC3 protects secretory epithelia from Ca2+-dependent
toxicity. Gastroenterology 140, 2107–2115, 2115.e2101–e2104. doi:
10.1053/j.gastro.2011.02.052
Koike, Y., Kanai, T., Saeki, K., Nakamura, Y., Nakano, M., Mikami, Y., et al. (2012).
MyD88-dependent interleukin-10 production from regulatory CD11b(+)Gr-
1(high) cells suppresses development of acute cerulein pancreatitis in mice.
Immunol. Lett. 148, 172–177. doi: 10.1016/j.imlet.2012.08.008
Kukor, Z., Mayerle, J., Kruger, B., Toth, M., Steed, P. M., Halangk, W., et al. (2002).
Presence of cathepsin B in the human pancreatic secretory pathway and its
role in trypsinogen activation during hereditary pancreatitis. J. Biol. Chem. 277,
21389–21396. doi: 10.1074/jbc.M200878200
Lee, H., Herrmann, A., Deng, J. H., Kujawski, M., Niu, G., Li, Z., et al.
(2009). Persistently activated Stat3 maintains constitutive NF-kappaB activity
in tumors. Cancer Cell 15, 283–293. doi: 10.1016/j.ccr.2009.02.015
Lee, M. S., Gu, D., Feng, L., Curriden, S., Arnush, M., Krahl, T., et al. (1995).
Accumulation of extracellular matrix and developmental dysregulation in the
pancreas by transgenic production of transforming growth factor-beta 1. Am. J.
Pathol. 147, 42–52.
Lerch, M. M., Saluja, A. K., Runzi, M., Dawra, R., and Steer, M. L. (1995). Luminal
endocytosis and intracellular targeting by acinar cells during early biliary pan-
creatitis in the opossum. J. Clin. Invest. 95, 2222–2231. doi: 10.1172/JCI117912
Lesina, M., Kurkowski, M. U., Ludes, K., Rose-John, S., Treiber, M., Kloppel, G.,
et al. (2011). Stat3/Socs3 activation by IL-6 transsignaling promotes progression
of pancreatic intraepithelial neoplasia and development of pancreatic cancer.
Cancer Cell 19, 456–469. doi: 10.1016/j.ccr.2011.03.009
Levine, B., and Kroemer, G. (2008). Autophagy in the pathogenesis of disease. Cell
132, 27–42. doi: 10.1016/j.cell.2007.12.018
Liang, X. H., Jackson, S., Seaman, M., Brown, K., Kempkes, B., Hibshoosh, H., et al.
(1999). Induction of autophagy and inhibition of tumorigenesis by beclin 1.
Nature 402, 672–676. doi: 10.1038/45257
Liby, K. T., Royce, D. B., Risingsong, R., Williams, C. R., Maitra, A., Hruban,
R. H., et al. (2010). Synthetic triterpenoids prolong survival in a transgenic
Frontiers in Physiology | Gastrointestinal Sciences January 2014 | Volume 4 | Article 415 | 12
Kolodecik et al. Pancreatitis to cancer pathways
mouse model of pancreatic cancer. Cancer Prev. Res. (Phila.) 3, 1427–1434. doi:
10.1158/1940-6207.CAPR-10-0197
Ling, J., Kang, Y., Zhao, R., Xia, Q., Lee, D. F., Chang, Z., et al. (2012). KrasG12D-
induced IKK2/beta/NF-kappaB activation by IL-1alpha and p62 feedforward
loops is required for development of pancreatic ductal adenocarcinoma. Cancer
Cell 21, 105–120. doi: 10.1016/j.ccr.2011.12.006
Lohr, J. M., and Jesenofsky, R. (2009). Pancreatic stellate cells and pancreatic
carcinoma: an unholy alliance. JOP 10, 472–473.
Mah, L. Y., and Ryan, K. M. (2012). Autophagy and cancer. Cold Spring Harb.
Perspect. Biol. 4, a008821. doi: 10.1101/cshperspect.a008821
Mantoni, T. S., Lunardi, S., Al-Assar, O., Masamune, A., and Brunner, T. B. (2011).
Pancreatic stellate cells radioprotect pancreatic cancer cells through beta1-
integrin signaling. Cancer Res. 71, 3453–3458. doi: 10.1158/0008-5472.CAN-
10-1633
Mareninova, O. A., Hermann, K., French, S. W., O’Konski, M. S., Pandol, S. J.,
Webster, P., et al. (2009). Impaired autophagic flux mediates acinar cell vacuole
formation and trypsinogen activation in rodent models of acute pancreatitis.
J. Clin. Invest. 119, 3340–3355. doi: 10.1172/JCI38674
Masamune, A., and Shimosegawa, T. (2009). Signal transduction in pancre-
atic stellate cells. J. Gastroenterol. 44, 249–260. doi: 10.1007/s00535-009-
0013-2
Masamune, A.,Watanabe, T., Kikuta, K., and Shimosegawa, T. (2009). Roles of pan-
creatic stellate cells in pancreatic inflammation and fibrosis. Clin. Gastroenterol.
Hepatol. 7, S48–S54. doi: 10.1016/j.cgh.2009.07.038
Mayer, J., Rau, B., Gansauge, F., and Beger, H. G. (2000). Inflammatory mediators
in human acute pancreatitis: clinical and pathophysiological implications. Gut
47, 546–552. doi: 10.1136/gut.47.4.546
Mews, P., Phillips, P., Fahmy, R., Korsten, M., Pirola, R., Wilson, J., et al. (2002).
Pancreatic stellate cells respond to inflammatory cytokines: potential role in
chronic pancreatitis. Gut 50, 535–541. doi: 10.1136/gut.50.4.535
Morris, J. P. T., Cano, D. A., Sekine, S., Wang, S. C., and Hebrok, M. (2010).
Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic
cancer precursor lesions in mice. J. Clin. Invest. 120, 508–520. doi: 10.1172/
JCI40045
Morton, J. P., Mongeau, M. E., Klimstra, D. S., Morris, J. P., Lee, Y. C.,
Kawaguchi, Y., et al. (2007). Sonic hedgehog acts at multiple stages during
pancreatic tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 104, 5103–5108. doi:
10.1073/pnas.0701158104
Moscat, J., and Diaz-Meco, M. T. (2012). p62: a versatile multitasker takes on
cancer. Trends Biochem. Sci. 37, 230–236. doi: 10.1016/j.tibs.2012.02.008
Mounzer, R., and Whitcomb, D. C. (2013). Genetics of acute and
chronic pancreatitis. Curr. Opin. Gastroenterol. 29, 544–551. doi:
10.1097/MOG.0b013e3283639383
Muili, K. A., Ahmad, M., Orabi, A. I., Mahmood, S. M., Shah, A. U., Molkentin,
J. D., et al. (2012). Pharmacological and genetic inhibition of calcineurin pro-
tects against carbachol-induced pathological zymogen activation and acinar
cell injury. Am. J. Physiol. Gastrointest. Liver Physiol. 302, G898–G905. doi:
10.1152/ajpgi.00545.2011
Mukherjee, P., Basu, G. D., Tinder, T. L., Subramani, D. B., Bradley, J. M., Arefayene,
M., et al. (2009). Progression of pancreatic adenocarcinoma is significantly
impeded with a combination of vaccine and COX-2 inhibition. J. Immunol. 182,
216–224.
Murphy, J. A., Criddle, D. N., Sherwood, M., Chvanov, M., Mukherjee, R.,
McLaughlin, E., et al. (2008). Direct activation of cytosolic Ca2+ signaling
and enzyme secretion by cholecystokinin in human pancreatic acinar cells.
Gastroenterology 135, 632–641. doi: 10.1053/j.gastro.2008.05.026
Murray, O. T., Wong, C. C., Vrankova, K., and Rigas, B. (2013). Phospho-sulindac
inhibits pancreatic cancer growth: NFATc1 as a drug resistance candidate. Int. J.
Oncol. 44, 521–529. doi: 10.3892/ijo.2013.2190
Nathan, C., and Ding, A. (2010). Nonresolving inflammation. Cell 140, 871–882.
doi: 10.1016/j.cell.2010.02.029
Navina, S., Acharya, C., Delany, J. P., Orlichenko, L. S., Baty, C. J., Shiva, S. S.,
et al. (2011). Lipotoxicity causes multisystem organ failure and exacerbates
acute pancreatitis in obesity. Sci. Transl. Med. 3, 107ra110. doi: 10.1126/sci-
translmed.3002573
Nemoda, Z., and Sahin-Toth, M. (2005). The tetra-aspartate motif in the activation
peptide of human cationic trypsinogen is essential for autoactivation control
but not for enteropeptidase recognition. J. Biol. Chem. 280, 29645–29652. doi:
10.1074/jbc.M505661200
Neuhofer, P., Liang, S., Einwachter, H., Schwerdtfeger, C., Wartmann, T., Treiber,
M., et al. (2013). Deletion of IkappaBalpha activates RelA to reduce acute pan-
creatitis inmice through up-regulation of Spi2A.Gastroenterology 144, 192–201.
doi: 10.1053/j.gastro.2012.09.058
Nishina, T., Yamaguchi, N., Gohda, J., Semba, K., and Inoue, J. (2009). NIK is
involved in constitutive activation of the alternative NF-kappaB pathway and
proliferation of pancreatic cancer cells. Biochem. Biophys. Res. Commun. 388,
96–101. doi: 10.1016/j.bbrc.2009.07.125
Ogami, Y., and Otsuki, M. (1998). Exocrine pancreatic physiology: overview.
Pancreas 16, 265–272. doi: 10.1097/00006676-199804000-00010
Ohmuraya, M., Hirota, M., Araki, M., Mizushima, N., Matsui, M., Mizumoto, T.,
et al. (2005). Autophagic cell death of pancreatic acinar cells in serine pro-
tease inhibitor Kazal type 3-deficient mice. Gastroenterology 129, 696–705. doi:
10.1016/j.gastro.2005.05.057
Ohta, T., Terada, T., Nagakawa, T., Tajima, H., Itoh, H., Fonseca, L., et al. (1994).
Pancreatic trypsinogen and cathepsin B in human pancreatic carcinomas and
associated metastatic lesions. Br. J. Cancer 69, 152–156. doi: 10.1038/bjc.
1994.25
Omary, M. B., Lugea, A., Lowe, A. W., and Pandol, S. J. (2007). The pancreatic
stellate cell: a star on the rise in pancreatic diseases. J. Clin. Invest. 117, 50–59.
doi: 10.1172/JCI30082
Osborn, O., and Olefsky, J. M. (2012). The cellular and signaling networks link-
ing the immune system and metabolism in disease. Nat. Med. 18, 363–374. doi:
10.1038/nm.2627
Ozaki, N., Ohmuraya, M., Hirota, M., Ida, S., Wang, J., Takamori, H., et al. (2009).
Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic can-
cer cells through the epidermal growth factor receptor. Mol. Cancer Res. 7,
1572–1581. doi: 10.1158/1541-7786.MCR-08-0567
Parekh, A. B. (2003). Store-operated Ca2+ entry: dynamic interplay between
endoplasmic reticulum, mitochondria and plasma membrane. J. Physiol. 547,
333–348. doi: 10.1113/jphysiol.2002.034140
Peery, A. F., Dellon, E. S., Lund, J., Crockett, S. D., McGowan, C. E.,
Bulsiewicz, W. J., et al. (2012). Burden of gastrointestinal disease in the
United States: 2012 update. Gastroenterology 143, 1179–1187.e1171–1173. doi:
10.1053/j.gastro.2012.08.002
Petersen, O. H., Gerasimenko, O. V., Tepikin, A. V., and Gerasimenko, J. V. (2011).
Aberrant Ca(2+) signalling through acidic calcium stores in pancreatic acinar
cells. Cell Calcium 50, 193–199. doi: 10.1016/j.ceca.2011.02.010
Pezzilli, R., Morselli-Labate, A. M., Mantovani, V., Romboli, E., Selva, P., Migliori,
M., et al. (2003). Mutations of the CFTR gene in pancreatic disease. Pancreas 27,
332–336. doi: 10.1097/00006676-200311000-00011
Pfutzer, R. H., Barmada, M.M., Brunskill, A. P., Finch, R., Hart, P. S., Neoptolemos,
J., et al. (2000). SPINK1/PSTI polymorphisms act as disease modifiers in famil-
ial and idiopathic chronic pancreatitis. Gastroenterology 119, 615–623. doi:
10.1053/gast.2000.18017
Philip, B., Roland, C. L., Daniluk, J., Liu, Y., Chatterjee, D., Gomez, S. B., et al.
(2013). A high-fat diet activates oncogenic Kras and COX2 to induce devel-
opment of pancreatic ductal adenocarcinoma in mice. Gastroenterology 145,
1449–1458. doi: 10.1053/j.gastro.2013.08.018
Phillips, P. A., McCarroll, J. A., Park, S., Wu, M. J., Pirola, R., Korsten,
M., et al. (2003). Rat pancreatic stellate cells secrete matrix metallopro-
teinases: implications for extracellular matrix turnover. Gut 52, 275–282. doi:
10.1136/gut.52.2.275
Phillips, P. A., Yang, L., Shulkes, A., Vonlaufen, A., Poljak, A., Bustamante, S., et al.
(2010). Pancreatic stellate cells produce acetylcholine and may play a role in
pancreatic exocrine secretion. Proc. Natl. Acad. Sci. U.S.A. 107, 17397–17402.
doi: 10.1073/pnas.1000359107
Raimondi, S., Lowenfels, A. B., Morselli-Labate, A. M., Maisonneuve, P., and
Pezzilli, R. (2010). Pancreatic cancer in chronic pancreatitis; aetiology, inci-
dence, and early detection. Best Pract. Res. Clin. Gastroenterol. 24, 349–358. doi:
10.1016/j.bpg.2010.02.007
Rakonczay, Z. Jr., Hegyi, P., Takacs, T., McCarroll, J., and Saluja, A. K. (2008). The
role of NF-kappaB activation in the pathogenesis of acute pancreatitis. Gut 57,
259–267. doi: 10.1136/gut.2007.124115
Romac, J. M., Ohmuraya, M., Bittner, C., Majeed, M. F., Vigna, S. R., Que, J.,
et al. (2010). Transgenic expression of pancreatic secretory trypsin inhibitor-
1 rescues SPINK3-deficient mice and restores a normal pancreatic phe-
notype. Am. J. Physiol. Gastrointest. Liver Physiol. 298, G518–G524. doi:
10.1152/ajpgi.00431.2009
www.frontiersin.org January 2014 | Volume 4 | Article 415 | 13
Kolodecik et al. Pancreatitis to cancer pathways
Rosenfeldt, M. T., O’Prey, J., Morton, J. P., Nixon, C., MacKay, G., Mrowinska, A.,
et al. (2013). p53 status determines the role of autophagy in pancreatic tumour
development. Nature 504, 296–300. doi: 10.1038/nature12865
Sah, R. P., Dudeja, V., Dawra, R. K., and Saluja, A. K. (2013). Cerulein-induced
chronic pancreatitis does not require intra-acinar activation of trypsinogen in
mice. Gastroenterology 144, 1076–1085.e1072. doi: 10.1053/j.gastro.2013.01.041
Salem, K., Brown, C. O., Schibler, J., and Goel, A. (2013). Combination
chemotherapy increases cytotoxicity of multiple myeloma cells by modifica-
tion of nuclear factor (NF)-kappaB activity. Exp. Hematol. 41, 209–218. doi:
10.1016/j.exphem.2012.10.002
Satoh, A., Gukovskaya, A. S., Nieto, J. M., Cheng, J. H., Gukovsky, I., Reeve, J. R.,
et al. (2004). PKC-delta and -epsilon regulate NF-kappaB activation induced
by cholecystokinin and TNF-alpha in pancreatic acinar cells. Am. J. Physiol.
Gastrointest. Liver Physiol. 287, G582–G591. doi: 10.1152/ajpgi.00087.2004
Scholz, A., Heinze, S., Detjen, K. M., Peters, M., Welzel, M., Hauff, P., et al. (2003).
Activated signal transducer and activator of transcription 3 (STAT3) supports
the malignant phenotype of human pancreatic cancer. Gastroenterology 125,
891–905. doi: 10.1016/S0016-5085(03)01064-3
Sendler, M., Dummer, A., Weiss, F. U., Kruger, B., Wartmann, T., Scharffetter-
Kochanek, K., et al. (2013). Tumour necrosis factor alpha secretion induces
protease activation and acinar cell necrosis in acute experimental pancreatitis
in mice. Gut 62, 430–439. doi: 10.1136/gutjnl-2011-300771
Senftleben, U., and Karin, M. (2002). The IKK/NF-kappa B pathway. Crit. Care
Med. 30, S18–S26. doi: 10.1097/00003246-200201001-00003
Sennello, J. A., Fayad, R., Pini, M., Gove, M. E., Ponemone, V., Cabay, R. J., et al.
(2008). Interleukin-18, together with interleukin-12, induces severe acute pan-
creatitis in obese but not in nonobese leptin-deficient mice. Proc. Natl. Acad.
Sci. U.S.A. 105, 8085–8090. doi: 10.1073/pnas.0804091105
Shi, C. S., Shenderov, K., Huang, N. N., Kabat, J., Abu-Asab, M., Fitzgerald, K.
A., et al. (2012). Activation of autophagy by inflammatory signals limits IL-
1beta production by targeting ubiquitinated inflammasomes for destruction.
Nat. Immunol. 13, 255–263. doi: 10.1038/ni.2215
Shrikhande, S. V., Martignoni, M. E., Shrikhande, M., Kappeler, A., Ramesh, H.,
Zimmermann, A., et al. (2003). Comparison of histological features and inflam-
matory cell reaction in alcoholic, idiopathic and tropical chronic pancreatitis.
Br. J. Surg. 90, 1565–1572. doi: 10.1002/bjs.4353
Shugrue, C. A., Alexandre, M., de Villalvilla, A. D., Kolodecik, T. R., Young, L. H.,
Gorelick, F. S., et al. (2012). Cerulein hyperstimulation decreases AMP-activated
protein kinase levels at the site of maximal zymogen activation. Am. J. Physiol.
Gastrointest. Liver Physiol. 303, G723–G732. doi: 10.1152/ajpgi.00082.2012
Siegel, R., Desantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., et al. (2012).
Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 62,
220–241. doi: 10.3322/caac.21149
Singh, N., Das, P., Datta Gupta, S., Sahni, P., Pandey, R. M., Gupta, S., et al. (2013).
Prognostic significance of extracellular matrix degrading enzymes-cathepsin L
and matrix metalloproteases-2 [MMP-2] in human pancreatic cancer. Cancer
Invest. 31, 461–471. doi: 10.3109/07357907.2013.820318
Smit, V. T., Boot, A. J., Smits, A. M., Fleuren, G. J., Cornelisse, C. J., and Bos, J. L.
(1988). KRAS codon 12 mutations occur very frequently in pancreatic adeno-
carcinomas. Nucleic Acids Res. 16, 7773–7782. doi: 10.1093/nar/16.16.7773
Spanier, B. W., Dijkgraaf, M. G., and Bruno, M. J. (2008). Trends and forecasts of
hospital admissions for acute and chronic pancreatitis in the Netherlands. Eur.
J. Gastroenterol. Hepatol. 20, 653–658. doi: 10.1097/MEG.0b013e3282f52f83
Steele, C. W., Jamieson, N. B., Evans, T. R., McKay, C. J., Sansom, O. J., Morton,
J. P., et al. (2013). Exploiting inflammation for therapeutic gain in pancreatic
cancer. Br. J. Cancer 108, 997–1003. doi: 10.1038/bjc.2013.24
Stienstra, R., van Diepen, J. A., Tack, C. J., Zaki, M. H., van de Veerdonk, F. L.,
Perera, D., et al. (2011). Inflammasome is a central player in the induction of
obesity and insulin resistance. Proc. Natl. Acad. Sci. U.S.A. 108, 15324–15329.
doi: 10.1073/pnas.1100255108
Strowig, T., Henao-Mejia, J., Elinav, E., and Flavell, R. (2012). Inflammasomes in
health and disease. Nature 481, 278–286. doi: 10.1038/nature10759
Sun, S. C. (2011). Non-canonical NF-kappaB signaling pathway.Cell Res. 21, 71–85.
doi: 10.1038/cr.2010.177
Sun, S. C. (2012). The noncanonical NF-kappaB pathway. Immunol. Rev. 246,
125–140. doi: 10.1111/j.1600-065X.2011.01088.x
Sun, W. H., Chen, G. S., Ou, X. L., Yang, Y., Luo, C., Zhang, Y., et al. (2009).
Inhibition of COX-2 and activation of peroxisome proliferator-activated recep-
tor gamma synergistically inhibits proliferation and induces apoptosis of human
pancreatic carcinoma cells. Cancer Lett. 275, 247–255. doi: 10.1016/j.canlet.
2008.10.023
Szabo, A., and Sahin-Toth, M. (2012). Increased activation of hereditary
pancreatitis-associated human cationic trypsinogenmutants in presence of chy-
motrypsin C. J. Biol. Chem. 287, 20701–20710. doi: 10.1074/jbc.M112.360065
Takamura, A., Komatsu, M., Hara, T., Sakamoto, A., Kishi, C., Waguri, S., et al.
(2011). Autophagy-deficient mice develop multiple liver tumors. Genes Dev. 25,
795–800. doi: 10.1101/gad.2016211
Threadgold, J., Greenhalf, W., Ellis, I., Howes, N., Lerch, M. M., Simon, P., et al.
(2002). The N34S mutation of SPINK1 (PSTI) is associated with a familial pat-
tern of idiopathic chronic pancreatitis but does not cause the disease. Gut 50,
675–681. doi: 10.1136/gut.50.5.675
Thrower, E. C., Diaz de Villalvilla, A. P., Kolodecik, T. R., and Gorelick,
F. S. (2006). Zymogen activation in a reconstituted pancreatic acinar cell
system. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G894–G902. doi:
10.1152/ajpgi.00373.2005
Thrower, E. C., Osgood, S., Shugrue, C. A., Kolodecik, T. R., Chaudhuri, A. M.,
Reeve, J. R. Jr., et al. (2008). The novel protein kinase C isoforms -delta and
-epsilon modulate caerulein-induced zymogen activation in pancreatic aci-
nar cells. Am. J. Physiol. Gastrointest. Liver Physiol. 294, G1344–G1353. doi:
10.1152/ajpgi.00020.2008
Thrower, E. C., Wang, J., Cheriyan, S., Lugea, A., Kolodecik, T. R.,
Yuan, J., et al. (2009). Protein kinase C delta-mediated processes in
cholecystokinin-8-stimulated pancreatic acini. Pancreas 38, 930–935. doi:
10.1097/MPA.0b013e3181b8476a
Treiber, M., Neuhofer, P., Anetsberger, E., Einwachter, H., Lesina, M., Rickmann,
M., et al. (2011). Myeloid, but not pancreatic, RelA/p65 is required for fibro-
sis in a mouse model of chronic pancreatitis. Gastroenterology 141, 1473–1485,
1485.e1471–e1477. doi: 10.1053/j.gastro.2011.06.087
Van Acker, G. J., Saluja, A. K., Bhagat, L., Singh, V. P., Song, A. M., and Steer, M.
L. (2002). Cathepsin B inhibition prevents trypsinogen activation and reduces
pancreatitis severity. Am. J. Physiol. Gastrointest. Liver Physiol. 283, G794–G800.
doi: 10.1152/ajpgi.00363.2001
Vincent, A., Herman, J., Schulick, R., Hruban, R. H., and Goggins, M. (2011).
Pancreatic cancer. Lancet 378, 607–620. doi: 10.1016/S0140-6736(10)62307-0
Vonlaufen, A., Phillips, P. A., Xu, Z., Goldstein, D., Pirola, R. C., Wilson, J. S., et al.
(2008). Pancreatic stellate cells and pancreatic cancer cells: an unholy alliance.
Cancer Res. 68, 7707–7710. doi: 10.1158/0008-5472.CAN-08-1132
Vonlaufen, A., Phillips, P. A., Xu, Z., Zhang, X., Yang, L., Pirola, R. C., et al. (2011).
Withdrawal of alcohol promotes regression while continued alcohol intake pro-
motes persistence of LPS-induced pancreatic injury in alcohol-fed rats. Gut 60,
238–246. doi: 10.1136/gut.2010.211250
Walsby, E., Pearce, L., Burnett, A. K., Fegan, C., and Pepper, C. (2012). The
Hsp90 inhibitor NVP-AUY922-AG inhibits NF-kappaB signaling, overcomes
microenvironmental cytoprotection and is highly synergistic with fludarabine
in primary CLL cells. Oncotarget 3, 525–534.
Wang, W., Abbruzzese, J. L., Evans, D. B., Larry, L., Cleary, K. R., and Chiao,
P. J. (1999). The nuclear factor-kappa B RelA transcription factor is constitu-
tively activated in human pancreatic adenocarcinoma cells. Clin. Cancer Res. 5,
119–127.
Wartmann, T., Mayerle, J., Kahne, T., Sahin-Toth, M., Ruthenburger, M., Matthias,
R., et al. (2010). Cathepsin L inactivates human trypsinogen, whereas cathep-
sin L-deletion reduces the severity of pancreatitis in mice. Gastroenterology 138,
726–737. doi: 10.1053/j.gastro.2009.10.048
Wei, H., Wei, S., Gan, B., Peng, X., Zou, W., and Guan, J. L. (2011). Suppression of
autophagy by FIP200 deletion inhibits mammary tumorigenesis. Genes Dev. 25,
1510–1527. doi: 10.1101/gad.2051011
Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. L., and Ferrante,
A.W. Jr. (2003). Obesity is associated withmacrophage accumulation in adipose
tissue. J. Clin. Invest. 112, 1796–1808. doi: 10.1172/JCI19246
Weiss, F. U., Halangk, W., and Lerch, M. M. (2008). New advances in pancreatic cell
physiology and pathophysiology. Best Pract. Res. Clin. Gastroenterol. 22, 3–15.
doi: 10.1016/j.bpg.2007.10.017
Wharry, C. E., Haines, K. M., Carroll, R. G., and May, M. J. (2009). Constitutive
non-canonical NFkappaB signaling in pancreatic cancer cells. Cancer Biol. Ther.
8, 1567–1576. doi: 10.4161/cbt.8.16.8961
Whitcomb, D. C. (2011). Genetics and alcohol: a lethal combination in pan-
creatic disease? Alcohol. Clin. Exp. Res. 35, 838–842. doi: 10.1111/j.1530-
0277.2010.01409.x
Frontiers in Physiology | Gastrointestinal Sciences January 2014 | Volume 4 | Article 415 | 14
Kolodecik et al. Pancreatitis to cancer pathways
Whitcomb, D. C. (2012). Genetics of alcoholic and nonalcoholic pancreatitis. Curr.
Opin. Gastroenterol. 28, 501–506. doi: 10.1097/MOG.0b013e328356e7f3
Whitcomb, D. C., Gorry, M. C., Preston, R. A., Furey, W., Sossenheimer, M.
J., Ulrich, C. D., et al. (1996). Hereditary pancreatitis is caused by a muta-
tion in the cationic trypsinogen gene. Nat. Genet. 14, 141–145. doi: 10.1038/
ng1096-141
White, E. (2012). Deconvoluting the context-dependent role for autophagy in
cancer. Nat. Rev. Cancer 12, 401–410. doi: 10.1038/nrc3262
Wilson, J. S., and Apte, M. V. (2003). Role of alcohol metabolism in alcoholic
pancreatitis. Pancreas 27, 311–315. doi: 10.1097/00006676-200311000-00007
Wilson, J. S., Apte, M. V., Thomas, M. C., Haber, P. S., and Pirola, R. C. (1992).
Effects of ethanol, acetaldehyde and cholesteryl esters on pancreatic lysosomes.
Gut 33, 1099–1104. doi: 10.1136/gut.33.8.1099
Wiseman, M. (2008). The secondWorld Cancer Research Fund/American Institute
for Cancer Research expert report. Food, nutrition, physical activity, and the
prevention of cancer: a global perspective. Proc. Nutr. Soc. 67, 253–256. doi:
10.1017/S002966510800712X
Witt, H., Luck, W., Hennies, H. C., Classen, M., Kage, A., Lass, U., et al.
(2000). Mutations in the gene encoding the serine protease inhibitor, Kazal
type 1 are associated with chronic pancreatitis. Nat. Genet. 25, 213–216. doi:
10.1038/76088
Xu, Z., Vonlaufen, A., Phillips, P. A., Fiala-Beer, E., Zhang, X., Yang, L., et al. (2010).
Role of pancreatic stellate cells in pancreatic cancer metastasis. Am. J. Pathol.
177, 2585–2596. doi: 10.2353/ajpath.2010.090899
Xue, J., Nguyen, D. T., and Habtezion, A. (2012). Aryl hydrocarbon receptor reg-
ulates pancreatic IL-22 production and protects mice from acute pancreatitis.
Gastroenterology 143, 1670–1680. doi: 10.1053/j.gastro.2012.08.051
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., et al. (2010). Distant
metastasis occurs late during the genetic evolution of pancreatic cancer. Nature
467, 1114–1117. doi: 10.1038/nature09515
Yadav, D., and Lowenfels, A. B. (2013). The epidemiology of pancre-
atitis and pancreatic cancer. Gastroenterology 144, 1252–1261. doi:
10.1053/j.gastro.2013.01.068
Yang, L., Li, P., Fu, S., Calay, E. S., and Hotamisligil, G. S. (2010). Defective hep-
atic autophagy in obesity promotes ER stress and causes insulin resistance. Cell
Metab. 11, 467–478. doi: 10.1016/j.cmet.2010.04.005
Yang, S., and Kimmelman, A. C. (2011). A critical role for autophagy in pancreatic
cancer. Autophagy 7, 912–913. doi: 10.4161/auto.7.8.15762
Yang, S., Wang, X., Contino, G., Liesa, M., Sahin, E., Ying, H., et al. (2011).
Pancreatic cancers require autophagy for tumor growth. Genes Dev. 25,
717–729. doi: 10.1101/gad.2016111
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-
Sananikone, E., et al. (2012). Oncogenic Kras maintains pancreatic tumors
through regulation of anabolic glucose metabolism. Cell 149, 656–670. doi:
10.1016/j.cell.2012.01.058
Yokota, T., Denham, W., Murayama, K., Pelham, C., Joehl, R., and Bell, R. H. Jr.
(2002). Pancreatic stellate cell activation and MMP production in experimental
pancreatic fibrosis. J. Surg. Res. 104, 106–111. doi: 10.1006/jsre.2002.6403
Yonezawa, S., Higashi, M., Yamada, N., and Goto, M. (2008). Precursor lesions of
pancreatic cancer. Gut Liver 2, 137–154. doi: 10.5009/gnl.2008.2.3.137
Yue, Z., Jin, S., Yang, C., Levine, A. J., and Heintz, N. (2003). Beclin 1, an
autophagy gene essential for early embryonic development, is a haploinsuffi-
cient tumor suppressor. Proc. Natl. Acad. Sci. U.S.A. 100, 15077–15082. doi:
10.1073/pnas.2436255100
Zyromski, N. J., Mathur, A., Pitt, H. A., Lu, D., Gripe, J. T., Walker, J. J., et al.
(2008). A murine model of obesity implicates the adipokine milieu in the
pathogenesis of severe acute pancreatitis. Am. J. Physiol. Gastrointest. Liver
Physiol. 295, G552–G558. doi: 10.1152/ajpgi.90278.2008
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 19 December 2013; accepted: 30 December 2013; published online:
January 2014.
Citation: Kolodecik T, Shugrue C, AshatM and Thrower EC (2014) Risk factors for
pancreatic cancer: underlying mechanisms and potential targets. Front. Physiol. 4:415.
doi: 10.3389/fphys.2013.00415
This article was submitted to Gastrointestinal Sciences, a section of the journal
Frontiers in Physiology.
Copyright © 2014 Kolodecik, Shugrue, Ashat and Thrower. This is an open-access
article distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
www.frontiersin.org January 2014 | Volume 4 | Article 415 | 15
16
